

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Developing a Core Outcome Set on Traditional Chinese Medicine (COS-TCM) for Chronic Heart Failure (CHF): A study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-047148
Article Type:	Protocol
Date Submitted by the Author:	19-Nov-2020
Complete List of Authors:	<p>Zhang, Mingyan; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center</p> <p>Chua, Hui Zi; Tianjin University of Traditional Chinese Medicine, Evidence-based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center</p> <p>Niu, Bohan; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center</p> <p>Zheng, Wenke; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center</p> <p>Li, Kai; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center</p> <p>Zhang, Junhua; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center</p> <p>Zhang, Boli; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center</p>
Keywords:	Heart failure < CARDIOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Herbal medicine < THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Developing a Core Outcome Set on Traditional Chinese Medicine (COS-TCM) for Chronic
4 Heart Failure (CHF): A study protocol
5

6 Mingyan Zhang^{1,2#}, Hui Zi Chua^{1,2#}, Bohan Niu^{1,2}, Wenke Zheng^{1,2}, Kai Li^{1,2},
7 Junhua Zhang^{1,2*}, Boli Zhang²
8
9

10
11 1 Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine,
12 Tianjin 301617, China
13

14
15 2 Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China
16

17 # These authors contributed equally to the manuscript.
18

19 *Correspondence:
20

21
22 Junhua Zhang, Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese
23 Medicine (e-mail: zjhtcm@foxmail.com).
24
25
26
27
28
29
30
31
32

33 **ABSTRACT**
34

35 **Introduction** Chronic heart failure (CHF) is a serious and advanced stage of various
36 cardiovascular diseases and portends poor prognosis. An increase in clinical studies has
37 reported the effectiveness of traditional Chinese medicine (TCM). For example, intravenous
38 Chinese medicine can significantly improve cardiac function and biomarkers in CHF patients.
39 However, there exists inconsistency, lack of practicality and unclear reporting of outcomes in
40 these clinical trials causing difficulty in the comparison of results across similar studies
41 during data synthesis. A core outcome set (COS) can help in the standardization of outcomes
42 reported across studies from the same healthcare area. The aim of this study is to develop a
43 COS on TCM for CHF (COS-TCM-CHF) to reduce heterogeneity in reporting and improve
44 quality assessment in clinical trials to support data synthesis in addressing the effectiveness
45 of TCM treatment.
46
47
48
49
50
51
52
53

54
55 **Methods and analysis** This study will include constructing an outcome pool which will
56 identify potential outcomes through systematic reviews of TCM RCTs, 2 clinical registry
57 databases, semi-structured interviews of patients and the clinicians' questionnaire. According
58
59
60

1
2
3 to the characteristics of TCM and a taxonomy recommended by the Core Outcome Measures
4 in Effectiveness Trials (COMET) initiative, all outcomes in the outcome pool will be
5 classified into different domains. A preliminary list of outcomes which will then be used in
6 the Delphi survey is generated using a certain criteria based on the length of the pool. The
7 Delphi survey will include two rounds with 7 key stakeholder groups to select candidate
8 items for a consensus meeting. A final COS-TCM-CHF will be developed at a face-to-face
9 consensus meeting involving representatives from the different stakeholders.

10
11
12
13
14
15
16 **Ethics and dissemination** Ethical approval of this study has been granted by Evidence-
17 based Medicine Centre of Tianjin University of Traditional Chinese Medicine Research
18 Ethics Committee (TJUTCMEC201200002). We will disseminate our research findings of
19 the final COS on the website of Chinese Clinical Trials for Core Outcome Set (ChiCOS),
20 with open access publications and present at international conferences to reach a wide range
21 of knowledge users.
22
23
24
25
26

27
28 **Trial Registration number** This study is registered with the COMET initiative study 1486
29 (available at <http://www.comet-initiative.org/studies/details/1486>).
30
31

32 **Keywords** chronic heart failure, core outcome set, methodology, traditional Chinese
33 Medicine
34
35

36 37 38 39 **Strengths and limitation of this study**

- 40 ◆ Systematic reviews for RCTs in CHF on TCM and identifying additional potential
41 outcomes from 2 clinical trial registry databases (an international-based and a China-
42 based)
- 43 ◆ Semi-structured interviews will involve both patients, as well as clinicians, serving as a
44 qualitative method in the COS development
- 45 ◆ Limiting the preliminary checklist of outcomes to a minimum of 100 items to avoid low
46 response efficiency in the Delphi survey
- 47 ◆ The Delphi survey and consensus meeting will include key stakeholders such as patient
48 representatives, healthcare professionals and COS users.
49
50
51
52
53
54
55
56
57
58
59
60

- ◆ TCM is mainly used in China. Hence, the geographical spread of the representatives of stakeholders will be a limitation but able to address the perspective of Chinese population.

INTRODUCTION

Background

Chronic heart failure (CHF), caused by abnormalities changes in cardiac structure and function, is a serious and advanced stage of various cardiovascular diseases and portends poor prognosis[1]. The prevalence of CHF is rising with the aging population and changes in lifestyle habits. It is anticipated that the prevalence of heart failure (HF) will increase 46% from 2012 to 2030, with an estimate of more than 8 million adults with HF in United States[2]. China has an incidence rate of approximately 0.9% in HF[3], with 500,000 new HF patients being diagnosed every year and the mortality of CHF in five years is as high as 60% - 80%[4]. Currently, renin-angiotensin-aldosterone system (RAAS) inhibition, β -receptor blockers, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blocker (ARB) have been the mainstream of medical therapy for CHF[5]. However, prolonged uses of these drugs may cause severe side effects and could result in declining quality of life for CHF patients. Traditional Chinese Medicine (TCM) is commonly used in combination with conventional therapy to treat CHF in China, improving clinical symptoms and health status on the premise of long-term survival.

Syndrome differentiation is used as a treatment principle for TCM, whereby the TCM syndrome exhibits the severity and stages of the disease combining with the patient's constitution. It is determined by using the four methods of diagnosis: tongue examination, history taking (inquiry), listening and smelling examination, palpation (pulse taking, abdominal examination, etc.). Based on the different syndromes of a disease, a combination of herbs or a TCM formula (containing complex compounds in specific ratios and doses) will be used for the treatment. Early intervention of TCM may reduce the adverse effects due to long term usage of conventional drugs, as well as improving the immune and physical function of the patients to minimize re-hospitalization caused by acute attacks of CHF[6]. Clinical studies have reported the effectiveness of TCM such as Qishen Yiqi dripping pills, Shenfu or Shengmai injection can also significantly improve the cardiac function and

1
2
3 biomarkers in CHF patients[7]. However, these results should be dealt with caution due to a
4 lack of methodological quality for TCM related clinical studies. Significant inconsistency in
5 the outcomes collected and reported across these studies brings about difficulty in combining
6 or comparing results during systematic reviews and meta-analyses[8]. In addition, these
7 outcomes may lack relevance to patients and clinicians, leading to research waste.
8
9

10
11
12 A way to address this existing problem in the heterogeneity of outcomes is to
13 standardize outcomes reported across CHF-TCM studies, so that outcomes can be meaningful
14 for patients, health care professionals and other relevant stakeholders to make prudent
15 healthcare decision. This could be achieved by the development and implementation of a core
16 outcome set (COS). A COS is an agreed standardized set of outcomes, which should be
17 measured and reported, as a minimum, in all trials for the same healthcare area[9]. The role
18 of developing a COS is to improve the consistency in outcome reporting and to measure
19 appropriate and important outcomes in healthcare trials. A significant increase in registered
20 COS studies on Core Outcome Measures in Effectiveness Trials (COMET) website reflected
21 the increasing awareness of the unwarranted variation in outcome collection and
22 reporting[10]. However, it is worthy to note that the purpose of a standardized outcome set,
23 or COS is not to create new outcomes, but to select those outcomes which matter the most to
24 the various stakeholders such as clinicians, researchers, policy makers and patients.
25
26
27
28
29
30
31
32
33
34

35
36 In China, there is a rising emphasis on the development of TCM for chronic disease care
37 and prevention, with an increased usage of TCM related interventions on chronic diseases,
38 particularly in heart disease, stroke, cancer and diabetes[11]. This is reflected by the
39 uniqueness of TCM in its ability to treat patients by altering their “inner environment” or
40 simply, to regulate as a whole in the form of improving the patient’s physical function, self-
41 adaptive ability and immune function, which is beneficial for chronic diseases management
42 and prevention. With more research on TCM being carried out in China, guidance to improve
43 the value of trials and provide strong evidence to evaluate the true effectiveness of TCM
44 treatments is urgently required.
45
46
47
48
49
50

51
52 At present, there are two related COSs for HF recorded in the COMET database. The
53 Heart Failure Association of the European Society of Cardiology (HFA-ESC) developed a
54 consensus for HF endpoints in clinical trials published in 2013, with a 1 year follow up on the
55 defined outcomes across different regions between May 2011 and April 2013 , reflecting on
56 the higher rate for all-cause mortality in acute HF than CHF across the 1 year span[12-13].
57
58
59
60

1
2
3 Another was the 17-item standardized set of outcome measurement for HF established by
4 The International Consortium for Health Outcomes Measurement (ICHOM) on March 2020,
5 which selectively addressed functional, psychosocial, burden of care, and survival outcome
6 domains[14]. Though the stakeholders involved in the COS development for HF represented
7 an international perspective and included patient-reported outcomes, the standardized
8 outcome set in both COSs may be biased toward Western patient populations, lacking
9 engagement in the Chinese patient population and Chinese healthcare professionals, and does
10 not involve any outcomes related to TCM syndromes or its characteristics. Therefore, it is
11 important to develop a COS that specifically address the need of CHF studies using TCM
12 treatment, which can represent all stakeholders for this specific intervention. The COS will
13 include outcomes with TCM characteristics and achieve consensus in Chinese research or
14 clinical experts and its patient population.
15
16
17
18
19
20
21
22
23
24

25 **Objective**

26
27 Currently, there is no study on COS development for CHF in TCM related clinical studies.
28 The objective of this study is to develop a COS-TCM for CHF (COS-TCM-CHF) and this
29 study protocol is written with reference to the Core Outcome Set-STAndards for
30 Reporting(COS-STAR)[15], the Core Outcome Set-STAndards for Development(COS-
31 STAD)[16] and the Core Outcome Set-STAndardised Protocol Items (COS-
32 STAP) statement[17].
33
34
35
36
37
38
39

40 **Scope**

41 The health condition for this study is on CHF. CHF patients aged 18 and above will be
42 included. This COS will cover all TCM related interventions, including herbal medicine
43 decoction, Chinese patent medicine, extracts of herbal medicine, intravenous Chinese
44 medicine, acupuncture, cupping, Tuina, moxibustion and other rehabilitation therapy of
45 TCM. The COS-TCM-CHF will be implemented in all future studies that examine outcomes
46 of TCM related interventions for CHF.
47
48
49
50
51
52

53 **Registration**

54
55 This COS study has been registered on the COMET website (study 1486, available at
56 <http://www.comet-initiative.org/Studies/Details/1486>)
57
58
59
60

METHODS AND ANALYSIS

Steering committee membership

The steering committee will include 10 members, who are experts from different research fields. They include 3 TCM and 3 Western medicine clinical experts in the field of cardiology, 2 methodologists, 1 journal editor, 1 COS developer and 1 patient representative with CHF. The steering committee will review this protocol and provide guidance at each stage of the study process, as well as resolving any disagreements during the process. The committee will also attend and facilitate the consensus meeting as well as to engage COS uptake in the post development stage. All members of the steering committee membership will be co-authors of the COS-TCM-CHF.

Working group

The working group will be made up of 15 members, including TCM and Western medicine clinicians, methodologists, as well as professors and postgraduates from Chinese Clinical Trials COS Research Centre (ChiCOS), Tianjin University of TCM (TJUTCM), China. The role of the working group will include organising regular meetings, facilitating communication and hold discussion meetings to seek advice from the Steering committee if there are any differences to be resolved.

Stakeholders involvement

We will invite 7 groups of stakeholders to participate in the development of COS-TCM-CHF, which include healthcare professionals, patients or their representatives, COS developers, COS users (clinical trialists, systematic reviewers and clinical guideline developers), methodologists, policy makers and journal editors. The recruitment of stakeholders is as follows:

1. Western medicine and TCM healthcare professionals specialising in cardiology, with at least 5 years of clinical experience and academic qualifications of postgraduate and above. They will be selected from the China Association of Chinese Medicine (CACM) and Chinese Society of Cardiology (CSC).

2. Patients diagnosed with CHF possessing a moderate level of literacy and communication from inpatient wards and outpatient clinics of 4 TJUTCM affiliated hospitals.
3. COS developers, especially with relevant TCM experience via searching published or ongoing COS studies registered on COMET website.
4. Methodologists, COS users and journal editors will be invited by sampling with the help of the Chinese Cochrane Centre and TJUTCM Evidence-Based Medicine (EBM) Research Centre.
5. Policy makers in public health decision will be selected by CACM.

Patient and public involvement

Patients or their representatives will be involved in the semi-structured interviews, two rounds of Delphi survey and the final consensus meeting. We will recruit patients or their representatives who are eloquent to ensure efficient communication. Addressing outcomes that are important to patients is crucial for COS-TCM-CHF development, hence patients' experiences in the management of CHF will contribute to a large extent in the development process.

Design

The study design for COS-TCM-CHF has been informed by COMET Initiative Handbook, with reference to the guidelines from COS-STAD recommendations and COS-STAP, which will be conducted in five stages (Fig.1):

1. Identifying potential outcomes and constructing an outcome pool. (Stage 1)
2. Merging outcomes and grouping under outcome domains (Stage 2)
3. Generating a preliminary list of outcomes. (Stage 3)
4. Conducting a 2-round Delphi survey to select candidate items for consensus meeting. (Stage 4)
5. Hold a consensus meeting to determine the final COS-TCM-CHF. (Stage 5)

Stage 1 Identifying potential outcomes and constructing an outcome pool

1
2
3 The purpose of a COS development is not to create new outcomes, but to essentially screen
4 out the most important outcomes which concern the most to all stakeholders through a series
5 of consensus process based on identifying all potential outcomes related to healthcare
6 professionals, researchers and public health decision makers in a specific healthcare field or
7 disease. We will identify potential outcomes by constructing an outcome pool for COS-TCM-
8 CHF development through the four methods:
9
10
11
12

- 13
14 1. Conducting systematic review to collect currently reported outcomes from published
15 literature in TCM related clinical studies for CHF.
16
- 17
18 2. Identifying potential outcomes reported in international and Chinese clinical trial registry
19 databases.
20
- 21
22 3. Patients' semi-structured interviews to collect outcomes which matter most to the patients
23 or their representatives.
24
- 25
26 4. Clinicians' questionnaire survey to collect outcomes which are of interest to the healthcare
27 professionals
28
29
30

31 **Method 1: Systematic review of published literature**

32 *Search Strategy*

33
34
35 We will conduct a comprehensive search strategy from 8 English and Chinese databases. 4
36
37 English databases include PubMed, the Cochrane Library, Embase and Web of Science and 4
38 Chinese databases include China National Knowledge Infrastructure (CNKI), WanFang
39 Database (WanFang), SinoMed and TCM Clinical Evidence Database System (EVDS-TCM),
40
41 Randomized clinical trials (RCTs) of CHF with TCM related interventions published in from
42 2015 to 2020 will be included. The search strategy for English database is shown in
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Eligibility criteria

The inclusion and exclusion criteria for the systematic review of published literature is shown
in Table 1.

Table 1 Inclusion and Exclusion criteria of the systematic review for published literature

	Inclusion criteria	Exclusion criteria
Types of literature	Randomized controlled trials	Unable to retrieve full texts
Participant	Patients diagnosed with CHF*, above 18 years of age	Patients with other comorbidities or in a more critical condition
Intervention	<ul style="list-style-type: none"> • Intervention in treatment group: TCM related treatments which include oral or intravenous herbal medication, Chinese patent medicine, acupuncture, Tuina and acupoint application. • Intervention in control group: No limitation 	None
Outcomes	No restriction	No reported outcomes
Language	Chinese and English	Published in Chinese non-core journals

*According to "Guidelines for the diagnosis and treatment of Heart failure in China (2018)" or "American College of Cardiology/American Heart Association (ACC/AHA) guidelines (2016)"

Literature screening and data extraction

Two reviewers will independently screen the literature, extract data and cross-check them according to the inclusion and exclusion criteria. For the missing information of some studies, we will try our best to contact the relevant authors to provide them. If not possible, the study will be excluded. Any disagreements will be resolved through discussion after a thorough reading of the paper or by consulting with the third researcher.

An extraction table will be designed by the working group to collect relevant information involving the study design, setting, demographics of participants, types of intervention and outcomes. Data extracted on the outcomes reported will include the name, definition, measurement timepoints and measurement instruments or methods. Four principles of data extraction are as follows:

1. Data extracted will be performed by two reviewers which will then be compared and cross-checked. Any disagreements will be resolved by a senior researcher.
2. Extracted verbatim of the outcomes reported will be retained to ensure authenticity and traceability from the original data.
3. The free-text field is placed in the extraction table to record special circumstances at any time.
4. Any alteration of the data extracted during the process will be recorded.

Furthermore, we will assess the reporting quality of outcomes reported in the included studies. The method of this assessment is shown in Table 2 with reference to other COS studies[18-20].

Table 2 Seven items assessment of the reporting quality of outcome measures

No.	Criterion	Yes	No
1	Whether the outcome was clearly stated as primary or secondary outcome.	1 point	0 point
2	Whether the outcome was defined or not. Outcomes were considered defined if text of their meaning or a citation was provided.	1 point	0 point
3	It was clearly described how the outcomes are measured or the outcome measurement (indicators and/or tools used, if relevant).	1 point	0 point
4	It was clearly described by whom the outcomes are measured.	1 point	0 point
5	It was clearly described the time points and time period at or during which outcome was measured.	1 point	0 point
6	Are methods used to enhance the quality of outcome measurement (for example, repeated measurement, training) if appropriate?	1 point	0 point
7	The reporting of outcomes was consistent throughout the article. There is no unambiguous reporting that makes it confusing for the reader to assess what has been done.	1 point	0 point

Method 2: International and Chinese clinical trial registry databases

1
2
3 We will search Chinese Clinical Trial Registry (ChiCTR) and Clinical trials.gov registry
4 using the key word “heart failure” from inception to 2020. The protocols registered of CHF
5 RCTs with TCM interventions will be included with reference to the same inclusion and
6 exclusion criteria listed in Table 1. For literature screening and data extraction of clinical trial
7 registration protocols, similar technique will be applied as per the above mentioned
8 systematic review of published literature. Subsequently, data extracted will be analyzed and
9 outcomes will be aggregated with the list of potential outcomes derived from systematic
10 review of published literature, patients’ semi-structured interviews and clinicians’
11 questionnaire surveys(as described in Method 3 and 4 later). Additionally, the reporting
12 quality of outcome measures from registered clinical studies will also be assessed using the
13 quality assessment score in Table 2.

23 **Method 3: Patients’ semi-structured interview**

26 *Participant selection and recruitment*

27
28
29 Patients ≥ 18 years of age, diagnosed with CHF (according to the clinical guidelines for the
30 diagnosis and treatment of chronic heart failure in China or "American College of
31 Cardiology/American Heart Association (ACC/AHA) guidelines 2016") previously or
32 currently under TCM treatment as well as their family members or caregivers will be invited
33 to participate in the semi-structured interview. Potential participants will be approached at the
34 cardiology department of inpatient wards and outpatient clinics in Grade 3A TJUTCM
35 affiliated First Hospital and TJUTCM affiliated Second Hospital, Grade 2A TJUTCM
36 affiliated Fourth Hospital, as well as TJUTCM affiliated BaoKang Community Hospital.
37 Patients or their representatives should possess a moderate level of literacy and
38 communication skills to ensure effective communication. Patients who are mentally ill or
39 have serious comorbidities will be excluded from the study. Informed consent is necessary to
40 recruit these participants for this study. It will be stressed that participants are under no
41 obligation to take part and they are free to withdraw at any time without affecting their
42 medical care or legal rights. In the event whereby the recruited patients have a language or
43 communication barrier, they will be represented by their caregivers.

56 *Sampling size*

1
2
3 Patients' perspective is important and essential throughout the development process.
4 Sampling for qualitative interviews should aim for a diversity of participants[21]. We will
5 consider the gender, age, CHF classification and treatment history of the potential
6 participants. As there is no consensus on the sample size of this qualitative research, and with
7 past experience of qualitative studies, we aim to recruit a sample size of 50 patients.
8
9

13 *Data collection*

16 The semi-structured interview will be conducted by qualified and trained investigator to
17 explain the study to the participants. Information sheets on the study will be given to the
18 participants and informed consent will be collected upon agreement on accepting the
19 interview. A questionnaire in Chinese language will be designed in advance for this semi-
20 structured interview. Socioeconomics and demographics information as well as the medical
21 history of the participants will be collected. The investigator will ask the participants what
22 outcomes are of importance to them in a face to face interview. In the event when the
23 participant is not able to answer, the trained investigator will provide the list of outcomes
24 collected from the systematic review of published literature and registered studies as a guide
25 to inform participants on outcomes. In addition, an open ended question will be asked in
26 order to allow patients to supplement with any other outcome which they deemed as
27 important. The interviewer will then fill in the questionnaire according to the reply by the
28 participant. All the interview will be audio recorded to aid traceability of any missing
29 information.
30
31
32
33
34
35
36
37
38
39
40

41 As the education of participants can vary, there is a potential limitation of healthcare
42 knowledge and comprehension ability. To ensure the smooth facilitation of the interview, the
43 questionnaires should be designed in manner for easy comprehension. The working group
44 will carry out a pilot-testing to strengthen and transform the nomenclature and medical
45 terminologies in the questions into spoken language which are easily comprehensible to the
46 participants. The outline of the semi-structured interview is as listed below:
47
48
49
50

- 51 1. "What kind of result from the CHF treatment do you think is the most important to you?"
- 52
- 53 2. "What is the change in your CHF management, symptoms or daily lifestyle do you
54 consider to be the most important in helping you to determine the effectiveness of the
55 treatment?"
56
57
58
59
60

1
2
3 3. "Which aspect of CHF treatment is of most concern to you or which aspects do you hope
4 to get better improvement?"
5

6
7 4. "After the treatment for CHF, what changes have made you feel better?"
8
9

10 **Method 4: Clinicians' questionnaire survey**

11 *Participant selection and recruitment*

12
13 Healthcare professionals, including TCM and western practitioners specialising in cardiology
14 with ≥ 5 years of clinical experience and a master's degree or above will be invited to
15 participate in the questionnaire surveys. Potential candidates will be approached at hospital
16 wards and outpatient clinics of TJUTCM affiliated First Hospital, TJUTCM affiliated Second
17 Hospital, TJUTCM affiliated Fourth Hospital and TJUTCM affiliated BaoKang Community
18 Hospital. Participation will be on a voluntary basis and informed consent is required if they
19 agreed to participate in the survey.
20
21
22
23
24
25
26
27
28

29 *Sampling size*

30
31
32 Though the outcomes collected will be more comprehensive if the sample size is larger, we
33 considered the feasibility and representativeness of the surveys. Generally, sampling in
34 qualitative studies is purposive, therefore the clinicians who will participate should range
35 from medical officers to senior experts in the field of cardiology. There is currently no
36 guideline for the sampling size for qualitative studies, hence based on our past experience and
37 previous COS studies, we will recruit a sample size of 80 participants. In the event when less
38 than 80 surveys are completed, there will be a further recruitment of clinicians from national
39 cardiology academic conferences until the sample size is reached.
40
41
42
43
44
45
46

47 **Data collection**

48
49
50 A predesigned questionnaire in paper form will be distributed to the healthcare professionals
51 or clinicians. Demographics information, educational and academic status of the clinicians
52 will be collected upon agreement to complete the questionnaire survey. Questionnaires are
53 being designed in an open-ended format and clinicians will have the freedom to fill in
54 outcomes which are of importance to them. There will be a limit to a maximum of 5
55 outcomes listed in order to achieve the selection of outcomes which are of high importance to
56
57
58
59
60

1
2
3 the clinicians. The list of outcomes collected from the questionnaires will be analyzed by the
4 working group.
5
6

7 **Data analysis**

8
9
10 Data analysis will be performed after collecting data from the 4 different methods. Outcomes
11 collected from literature or clinical registry databases as well as qualitative research (patients'
12 semi-structured interviews and clinicians' questionnaire surveys) will be imported into an
13 Excel table. These outcomes collected will form the outcome pool. The outcomes will be
14 labelled with numbers corresponding to the original studies or qualitative surveys for easy
15 reference and traceability. Upon completion of outcome labelling, the outcomes will then be
16 cross-checked and standardized. The methods of standardizing outcomes are as follows:
17
18
19
20
21
22

- 23 1. The outcomes are sorted according to their similarities.
- 24 2. Extracted verbatim of the outcomes will be standardized according to their original
25 description or definition, in order to address problems such as abbreviations, nicknames and
26 composite outcomes. The composite outcome will be separated into individual outcomes.
27
- 28 3. Duplicates will be removed from the outcome pool. Similar and overlapping outcomes will
29 be merged into their standardized terminologies.
30
- 31 4. Two researchers of the working group will record the corresponding number assigned to
32 the outcomes in the list as well as record the frequency of each outcome.
33
34
35
36
37
38
39

40 Finally, an outcome pool is constructed after the outcomes are standardized. The steering
41 committee will be consulted if there were any discrepancies in the process of outcome
42 standardization. And if there is no consensus reached on an outcome, the outcome will be
43 excluded.
44
45
46
47

48 **Stage 2 Merging outcomes and grouping under outcome domains**

49
50 After an outcome pool is constructed, outcomes will be merged and grouped under their
51 respective outcome domains recommended in previous COS studies[22]. Since COS-CHF-
52 TCM focuses on developing a set of outcomes to be implemented in TCM related studies, the
53 outcome classification with TCM characteristics will be added such as TCM syndrome
54 scoring scale. The process will be carried out by two researchers independently. After which
55
56
57
58
59
60

1
2
3 the classification of outcomes will be cross-checked. Any discrepancies will be resolved by a
4 third researcher from the steering committee.
5
6

7 **Stage 3 Generating a preliminary list of outcomes**

8
9 The outcome pool can be used as a preliminary list of outcomes in the questionnaire of the
10 Delphi process. However, this list of outcomes can be a long list. If the list of outcomes from
11 the outcome pool is directly taken as the preliminary list of outcomes, it may result in a low
12 response during Delphi survey. Based on previous experience in developing a COS,
13 participants involved in the Delphi survey were less willing to respond when there was a
14 large number of outcomes in the preliminary list, for instance needing more than 10 minutes
15 to complete the questionnaire. Furthermore, the scores of outcomes are likely to be too
16 concentrated, making it difficult to reach a consensus on the ranking of importance. As a
17 result, multiple rounds of Delphi survey will be required which lead to additional time and
18 resource wastage.
19
20

21 Therefore, it is important to shorten the list of outcome pool to establish a preliminary list of
22 outcomes, which of a suitable length to be used in the Delphi survey later (Stage 4). The
23 criteria for retaining or dropping the outcomes are as follows:
24
25

- 26 1. If the number of outcomes collected in the outcome pool is less than or equal to 100, all
27 outcomes will be retained in the preliminary list.
- 28 2. If the number of outcomes collected in the outcome pool is more than 100, the working
29 group will conduct an internal vote to drop the items in the outcome pool under the guidance
30 of the steering committee. If 90% of the members in the working group think that an item is
31 unnecessary to enter the preliminary list, the item will be removed. The remaining items will
32 then be included to form the preliminary list of outcomes.
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Stage 4 2-round Delphi survey**

48 ***Software***

49
50 The 2-round electronic Delphi survey will be conducted using a Delphi software developed
51 by ChiCOS, similar to the DelphiManager software implemented by COMET working group
52 for COS research. The Delphi software is programmed using Chinese language to cater to the
53 stakeholder groups in China. According to the preliminary list of outcomes, it can
54 automatically generate questionnaire for the Delphi survey and to display results of outcome
55
56
57
58
59
60

1
2
3 scoring from the participants and comparison over different stakeholder after each round of
4 survey is completed. The Delphi software is also equipped with a database containing the
5 information of pre-existing Delphi participants or experts shared by ChiCOS working group.
6
7

8 9 ***Selection of Delphi participants and sampling size***

10
11 Seven stakeholder groups will be invited to participate in the Delphi survey, which include
12 clinicians, CHF patients or their representatives, experienced COS developers,
13 methodologists, potential COS users (clinical trialists, systematic reviewers, clinical guideline
14 developers, etc.), policy makers and journal editors. The 3 key stakeholder groups as
15 mentioned in COS-STAD, namely the clinicians, patients or their representatives and COS
16 users are essential in COS development. Hence, we will invite at least 40 participants for
17 each of the 3 key stakeholder groups. For the group of clinicians, a 1:1 ratio will be fixed for
18 Western medicine doctors and TCM doctors. At least 15 participants will be invited for each
19 of the remaining stakeholder groups. We plan to invite approximately 210 participants for the
20 Delphi survey. It is beneficial for more participants to represent each stakeholder group in
21 order to convince future patients or other stakeholders of its value. Hence, there is no need to
22 specify an upper limit for the number of participants. The selection criteria for participants
23 from the different stakeholders was previously stated in the “Stakeholders involvement”
24 section. Relevant information of the selected participants (excluding patients) will be
25 recorded in the Delphi experts’ database system on ChiCOS website. It is noteworthy to
26 identify the pre-existing Delphi participants name list available on Delphi database system on
27 ChiCOS website shared by members of ChiCOS working group as well as other COS
28 developers. This set of name list can be used to supplement the Delphi participants for this
29 study.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 ***Delphi scoring***

46
47 The Delphi process will require each participant to consider the importance of each outcome
48 from the four aspects, namely importance on clinical value, recognizability of outcomes in
49 related studies, able to reflect the advantages of TCM effectiveness, as well as being
50 consistent and measurable . Participants will be asked to score each of the outcome items in
51 the preliminary checklist using a scoring scale of 1 to 9, with 1 to 3 is labelled as ‘not
52 important’, 4 to 6 labelled as ‘important but not critical’ and 7 to 9 labelled as ‘critical’[23].
53 Participants will have an option of ‘unsure’ if they are unable to assess the importance of the
54 outcome items.
55
56
57
58
59
60

Delphi round 1

The preliminary list of outcomes generated in Stage 3 will be used in the first round of Delphi survey. For the questionnaire of Delphi round 1, a brief summary of the COS study will be presented to the participants. Participants will need to select which stakeholder group they belong to and be asked to score all the outcome items. At the end of the questionnaire, there is an additional open question, “What other outcomes do you think are important but not included in this questionnaire?”, to allow participants to add new outcomes. Besides, participants will have the option to provide their suggestion in a free-text field at the end of each item. Upon agreeing to participate in the Delphi survey, participants are required to score all outcome items. If the list of questions in the survey is not completed, there will be a reminder to avoid any missing data. Participants will not be able to submit any incomplete questionnaire so as to ensure the integrity of the survey. In order to ensure the comprehensibility of the questionnaire, we will invite an language expert to assist in revising the outcome terminology into plain language. The questionnaire will be pilot-tested on a small group of participants before disseminating to all participants.

Participants (excluding patients) will be sent a personalised email outlining the study along with a link to the online questionnaire of Delphi round 1. And they will be asked to complete the survey within 3 weeks. A reminder email will be sent out at the end of week 2 to prompt completion of the survey. An inspection to assess the number of participants will be done near the end of week 2 by the working group. If the response rate of the Delphi survey (number of respondents / number of invited participants) is lower than 70%, the survey will be extended for 2 more weeks and a reminder email will be sent to the respective participants who did not respond. For the stakeholder group of patients or their representatives, the survey will be conducted face-to-face in inpatient wards or outpatient clinics by a trained investigator to complete the paper questionnaire. Both the online and paper questionnaires are of the same version. All participants are asked to score each item according to their importance. After completing the rating score, they will have the opportunity to add any other item which is not in the list but important to them.

The working group will collect all completed questionnaires and calculate the overall participant response rate for Delphi round 1. For each outcome item, the average score, the score distribution across different stakeholder groups as well as the number of participants from different stakeholders who have scored it will be summarized. If $\geq 70\%$ of the

1
2
3 participants in any stakeholder group considered the item to be “important” or “critical” (ie.
4 score of 4-9 points), the item will be included in the next round of Delphi. At the same time,
5 the working group will inspect and determine whether the newly added items by the
6 participants are duplicates in the preliminary list and only new and unique outcome will be
7 retained to be included in the next round for scoring. Duplicates or overlapping outcomes will
8 be removed and not enter the next round.
9
10
11
12
13

14 **Delphi round 2**

15
16 Participants who completed the first round will be invited to participate in Delphi round 2.
17 Response rate, the distribution of scores and participants’ own score for each outcome are
18 being presented to all participants. After considering the feedback from the first round,
19 participants will be asked to re-score the retained outcomes which have met the requirement
20 to enter the second round and score the newly added outcome items from the first round. If
21 the scores between the two rounds change drastically, for example a participant considered an
22 item in round 1 as “not important” (1-3points) and rescores the item as “critical” (7-9 points)
23 in round 2, he or she will need to provide the reason for the change in scores in the free-text
24 field. Participants are also able to provide any suggestions for each item in the survey.
25
26
27
28
29
30
31
32

33 Delphi round 2 survey will also be sent out electronically to all participants (excluding
34 patients or their representatives) by the Delphi software developed by ChiCOS. The survey
35 will be printed into hard copy similar to Delphi round 1 for patients to complete in the second
36 round. The survey should be completed within 3 weeks and a reminder email will be sent to
37 prompt completion of the survey at the end of week 2. If the response rate is lower than 70%,
38 the survey will be extended for 1 more week and a reminder email will be sent to the
39 respective participants who did not respond.
40
41
42
43
44

45 At the end of Delphi round 2, the participants’ response rate, the average score as well as the
46 score distribution for each outcome item are calculated. Participants’ score changes between
47 round 1 and 2 will be examined and verified, as well as summarizing the reasons for the
48 change in scores. Together with the reasons, the average score for each outcome in round 2 is
49 compared with that in round 1, so that we can assess attrition bias. There will not be any
50 source for missing data as we have made it compulsory for participants to complete all the
51 questions in the Delphi survey before submission.
52
53
54
55
56
57

58 **Stage 5 Consensus meeting**

The final phase of the developing COS-TCM-CHF is to hold a face-to-face consensus meeting after the Delphi process. The consensus meeting will be a one day event and 35 participants will be invited to confirm the final outcomes for COS-TCM-CHF. The consensus meeting will be held in Tianjin, China for the convenience of most participants. In the event where there are other major events such as the resurgence of Coronavirus outbreak, the meeting will be changed to online video conference.

Recruitment

We will invite participants from the different stakeholder groups who have completed the two rounds of Delphi survey to join the consensus meeting. Experts of the steering committee and members of the working group will also attend the meeting. We will draw lots to select representatives of the participants from each stakeholder group, including patient participants. If a representative from a stakeholder group is not available to attend the meeting, he or she will be replaced by another participant from the same stakeholder group.

Consensus definition

Consensus criteria will be specified a priori. The definition of the consensus are shown in Table 3, which was made according to the consensus previously used by other COSs developed and COMET recommendations[9,21,24]. Outcomes are classified into 3 categories: 'consensus in', 'consensus out' and 'no consensus'.

Table 3 Consensus definition		
Consensus classification	Description	Definition
Consensus in	Consensus that outcome should be included in COS	>70% of participants scoring 7-9 and <15% of participants scoring 1-3
Consensus out	Consensus that outcome should not be included in the COS	>70% of participants scoring 1-3 and <15% of participants scoring 7-9
No consensus	Uncertainty about importance of the outcome	Anything else

Consensus process and final decisions

After a short review of the COS-TCM-CHF study, the scoring results of Delphi round 2 will

1
2
3 be shown to all participants in the meeting. According to the consensus definition, outcomes
4 of “consensus in” will be prioritised to be included in the final COS and outcomes of
5 “consensus out” will be excluded. The participants will vote anonymously for the outcomes
6 rated as “no consensus”. After the voting, results will be calculated and outcomes achieving a
7 consensus will enter the final COS-TCM-CHF. In the process, all participants have the
8 opportunity to discuss any outcome. If there are any disputes, it will be settled by the Steering
9 committee through the nominal group technique (NGT)[25]. The final COS-TCM-CHF will
10 be developed which will include 4-10 core outcomes according to the COMET
11 recommendations[21].
12
13
14
15
16
17
18
19

20 **Fig. 1** Flow chart of the study design for COS-TCM-CHF

21 *List of abbreviations*

22
23
24
25 heart failure (HF), chronic heart failure (CHF), core outcome set (COS), traditional Chinese
26 medicine (TCM), Core outcome set on Traditional Chinese medicine (COS-TCM), Core
27 outcome set on Traditional Chinese medicine for chronic heart failure (COS-TCM-CHF),
28 Heart Failure Association of the European Society of Cardiology (HFA-ESC), The
29 International Consortium for Health Outcomes Measurement (ICHOM), Core Outcome
30 Measures in Effectiveness Trials (COMET), Core outcome set-STANDARDISED Protocol (COS-
31 STAP), reporting guidelines for studies developing COS protocol (COS-STAR), Chinese
32 Clinical Trials COS Research Centre (ChiCOS), Tianjin University of TCM (TJUTCM),
33 Core outcome set-STANDARDS for Development (COS-STAD), randomized clinical trials
34 (RCTs)
35
36
37
38
39
40
41
42
43
44

45 *Ethics and dissemination*

46 The study has obtained ethical approval through the Ethics Committee of the Evidence-based
47 Medicine Center, Tianjin University of Traditional Chinese Medicine, Ref:
48 TJUTCMEC201200002. Informed consent will be obtained from all participants who
49 participate in the semi-structured interviews, questionnaire survey and two rounds of the Delphi
50 survey. The study is registered with the COMET Initiative
51 (<http://www.cometinitiative.org/Studies/Details/1486>).
52
53
54
55
56

57 When the development of the COS is completed, it will be reported based on the items of the
58 Core Outcome Set-STANDARDS for Reporting (COS-STAR). The findings will be submitted for
59
60

1
2
3 publication in peer-reviewed and open access journals and will be presented at national and
4 international conferences on CHF. In addition, the results will be disseminated on the website
5 of Chinese clinical trials of COS(www. Chicos.org.cn). In addition, with the help of ChiCOS
6 and the China association of Chinese medicine, we hope to promote awareness of the COS
7 results and we intend to send the publication of the COS to all participants via emails or express
8 delivery to improve COS-TCM implementation.
9
10
11
12
13

14 ***Author affiliations***

15 1 Evidence-based medicine center, Chinese Medicine Institute, Tianjin University of
16 Traditional Chinese Medicine, Tianjin, China
17
18

19 2 Chinese Clinical Trials Core Outcome Set Research Center, Tianjin, China
20
21
22

23 ***Authors' contributions***

24
25 MZ and HZC wrote the paper and conceived the project. HZC contributed the English
26 translation of this protocol. MZ and JZ are the principal investigators of the study, and MZ
27 obtained the support of the National Natural Science Foundation of China. HZC, BN and KL
28 are responsible for conducting the systematic review. WZ and BZ provide supervision for the
29 project. All authors edited and critically revised the study protocol. All authors have read,
30 contributed to and approved the manuscript.
31
32
33
34
35

36 ***Funding***

37
38 This work was supported by the National Natural Science Foundation of China
39 (No.81473544).
40
41
42

43 ***Competing interests***

44
45 All authors declare that they have no competing interests.
46
47

48 ***Patient and public involvement***

49 Patients and/or the public were involved in the design, or conduct, or reporting, or
50 dissemination plans of this research. Refer to the Methods section for further details.
51
52

53 ***Patient consent for publication***

54
55 Not required
56
57

58 ***Provenance and peer review***

59
60 Not commissioned; externally peer reviewed.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Mingyan Zhang <https://orcid.org/0000-0002-4413-7784>

Hui Zi Chua <https://orcid.org/0000-0003-3927-9179>

Bohan Niu <https://orcid.org/0000-0002-3092-9879>

Kai Li <https://orcid.org/0000-0003-2724-338X>

Wenke Zheng <https://orcid.org/0000-0001-7963-5946>

Junhua Zhang <https://orcid.org/0000-0003-4043-1967>

Consent for publication

Not applicable

Availability of data and materials

Not applicable

References:

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016;18(8):891-975. doi:10.1002/ejhf.592
2. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation*. 2020;141(9):e139-e596. doi:10.1161/CIR.0000000000000757
3. R. Ariely et al. Heart Failure in China: A review of literature. *Drugs* 2013, 73(7):689-701.
4. Jun Huang. Epidemiology characteristics and preventive strategies of heart failure in China. *Chinese Journal of Heart and Rhythm Electronics* 2015,3(2):2-3.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013
6. Q Jia, L Wang, X Zhang et al. Prevention and treatment of chronic heart failure through traditional Chinese medicine: Role of the gut microbiota. *Pharmacological Research*. *Pharmacological Research* 151 (2020) 104552.
7. Wang Y, Wang Q, Li C, et al. A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure. *Curr Pharm Des*. 2017;23(34):5115-5124.
8. Zhang L, Zhang J, Chen J, et al. Clinical Research of Traditional Chinese Medicine Needs to Develop Its Own System of Core Outcome Sets [J]. *Evidence-Based Complementary and Alternat Med*, 2013; 2013:202703.
9. Williamson, P.R., Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider[J]. *Trials*, 2012. 13: p.132.
10. Elizabeth Gargon, Sarah L. Gorst, Paula R. Williamson. Choosing important health outcomes for comparative effectiveness research: 5th annual update to a systematic review of core outcome sets for research[J]. *PLoS ONE* 14(12): e0225980.
11. Fan X, Meng F, Wang D et al. Perceptions of traditional Chinese medicine for chronic disease care and prevention: a cross-sectional study of Chinese hospital-based health care professionals. *BMC Complement Altern Med*. 2018 Jul 6;18(1):209.
12. Zannad F, Garcia AA, Anker SD et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail*. 2013 Oct;15(10):1082-94.
13. Crespo-Leiro MG, Anker SD, Maggioni AP et al. Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail*. 2016 Jun;18(6):613-25. doi: 10.1002/ejhf.566. Erratum in: *Eur J Heart Fail*. 2017 Mar;19(3):438.
14. Burns DJP, Arora J, Okunade O et al. International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients. *JACC Heart Fail*. 2020 Mar;8(3):212-222.
15. Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, et al. (2016) Core Outcome Set–STAndards for Reporting: The COS-STAR Statement. *PLoS Med* 13(10): e1002148.
16. Kirkham JJ, Davis K, Altman DG, et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations[J]. *PLoS Med*, 2017. 14(11): p. e1002447.
17. Kirkham, J.J., Gorst, S., Altman, D.G. *et al*. Core Outcome Set-STANDARDISED Protocol Items: the COS-STAP Statement. *Trials* 20, 116 (2019).
18. Harman NL, Bruce IA, Callery P, et al. MOMENT--Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials*. 2013;14:70

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Alkhaffaf B, Blazeby JM, Williamson PR, et al. Reporting of outcomes in gastric cancer surgery trials: a systematic review. *BMJ Open* 2018;8:e21796.
 20. Heemskerk SCM, Rotteveel AH, Melenhorst J, Breukink SO, Kimman ML, Dirksen CD. Heterogeneous outcome reporting in adult slow-transit constipation studies: Systematic review towards a core outcome set. *J Gastroenterol Hepatol.* 2020;35(2):192–203.
 21. Williamson, P.R., Altman, D.G., Bagley, H. *et al.* The COMET Handbook: version 1.0. *Trials* 18, 280 (2017).
 22. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *J Clin Epidemiol.* 2018 Apr;96:84-92.
 23. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol.* 2011;64(4):395–400.
 24. de Blacam C, Baylis AL, Kirschner RE, Smith SM, Sell D, Sie KCY, Harris HE, Orr DJA. Protocol for the development of a core outcome set for reporting outcomes of management of velopharyngeal dysfunction. *BMJ Open.* 2020 Aug 13;10(8):e036824. doi: 10.1136/bmjopen-2020-036824. PMID: 32792441; PMCID: PMC7430341.
 25. Wiggins ST, Colby S, Moret L, McElrone M, Olfert MD, Riggsbee K, Opoku-Acheampong A, Kidd T. A Modified Nominal Group Technique (mNGT) - Finding Priorities in Research. *Am J Health Behav.* 2020 May 1;44(3):345-352. doi: 10.5993/AJHB.44.3.7. PMID: 32295682.




Fig. 1 Flow chart of the study design for COS-TCM-CHF

Supplementary File 1

#1 "chronic"[All Fields] OR "chronical"[All Fields] OR "chronically"[All Fields] OR "chronicities"[All Fields] OR "chronicity"[All Fields] OR "chronicization"[All Fields] OR "chronics"[All Fields] AND "heart failure"[MeSH Terms] OR "heart failure"[Title/Abstract] OR "cardiac failure"[Title/Abstract] OR "myocardial failure"[Title/Abstract] OR "cardiomyopath*"[Title/Abstract] OR "cardio renal syndrome"[Title/Abstract] OR "dyspnea paroxysmal"[Title/Abstract] OR "edema cardiac"[Title/Abstract] OR "heart failure diastolic"[Title/Abstract] OR "heart failure systolic"[Title/Abstract] OR "heart decompensation"[Title/Abstract] OR "decompensation heart"[Title/Abstract] OR "heart failure right sided"[Title/Abstract] OR "heart failure right sided"[Title/Abstract] OR "right sided heart failure"[Title/Abstract] OR "right sided heart failure"[Title/Abstract] OR "congestive heart failure"[Title/Abstract] OR "heart failure congestive"[Title/Abstract] OR "heart failure left sided"[Title/Abstract] OR "heart failure left sided"[Title/Abstract] OR "left sided heart failure"[Title/Abstract] OR "left sided heart failure"[Title/Abstract]

#2 "medicine, chinese traditional"[MeSH Terms] OR "chinese medicine"[Title/Abstract] OR "traditional chinese medicine"[Title/Abstract] OR "herbal medicine"[Title/Abstract] OR "chinese traditional"[Title/Abstract] OR "chinese herbal"[Title/Abstract] OR "oriental traditional"[Title/Abstract] OR "herb"[Title/Abstract] OR "herbs"[Title/Abstract] OR "Herbal"[Title/Abstract] OR "herbals"[Title/Abstract] OR "TCM"[Title/Abstract]

#3 "Acupuncture"[MeSH Terms] OR "acupuncture therapy"[MeSH Terms] OR "acupuncture treatment*"[Title/Abstract] OR "treatment acupuncture"[Title/Abstract] OR "therapy acupuncture"[Title/Abstract] OR "pharmacoacupuncture treatment"[Title/Abstract] OR (((((((("therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture therapy"[Title/Abstract]

#4 #2 OR #3 (((((((((((("medicine, chinese traditional"[MeSH Terms] OR "chinese medicine"[Title/Abstract] OR "traditional chinese medicine"[Title/Abstract] OR "herbal medicine"[Title/Abstract] OR "chinese traditional"[Title/Abstract] OR "chinese herbal"[Title/Abstract] OR "oriental traditional"[Title/Abstract] OR "herb"[Title/Abstract] OR "herbs"[Title/Abstract] OR "Herbal"[Title/Abstract] OR "herbals"[Title/Abstract] OR "TCM"[Title/Abstract] OR (((((((("Acupuncture"[MeSH Terms] OR "acupuncture therapy"[MeSH Terms] OR "acupuncture treatment*"[Title/Abstract] OR "treatment acupuncture"[Title/Abstract] OR "therapy acupuncture"[Title/Abstract] OR "pharmacoacupuncture treatment"[Title/Abstract] OR (((((((("therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture therapy"[Title/Abstract] AND "randomized controlled trial"[Publication Type]))

#5 #1 AND #4 (((((((((((((((((((((((("chronic"[All Fields] OR "chronical"[All Fields] OR "chronically"[All Fields] OR "chronicities"[All Fields] OR "chronicity"[All Fields] OR

1
2
3 "chronicization"[All Fields]) OR "chronics"[All Fields]) AND "heart failure"[MeSH Terms])
4 OR "heart failure"[Title/Abstract]) OR "cardiac failure"[Title/Abstract]) OR "myocardial
5 failure"[Title/Abstract]) OR "cardiomyopath*"[Title/Abstract]) OR "cardio renal
6 syndrome"[Title/Abstract]) OR "dyspnea paroxysmal"[Title/Abstract]) OR "edema
7 cardiac"[Title/Abstract]) OR "heart failure diastolic"[Title/Abstract]) OR "heart failure
8 systolic"[Title/Abstract]) OR "heart decompensation"[Title/Abstract]) OR "decompensation
9 heart"[Title/Abstract]) OR "heart failure right sided"[Title/Abstract]) OR "heart failure right
10 sided"[Title/Abstract]) OR "right sided heart failure"[Title/Abstract]) OR "right sided heart
11 failure"[Title/Abstract]) OR "congestive heart failure"[Title/Abstract]) OR "heart failure
12 congestive"[Title/Abstract]) OR "heart failure left sided"[Title/Abstract]) OR "heart failure
13 left sided"[Title/Abstract]) OR "left sided heart failure"[Title/Abstract]) OR "left sided heart
14 failure"[Title/Abstract]) AND (((((((("medicine, chinese traditional"[MeSH Terms] OR
15 "chinese medicine"[Title/Abstract]) OR "traditional chinese medicine"[Title/Abstract]) OR
16 "herbal medicine"[Title/Abstract]) OR "chinese traditional"[Title/Abstract]) OR "chinese
17 herbal"[Title/Abstract]) OR "oriental traditional"[Title/Abstract]) OR "herb"[Title/Abstract])
18 OR "herbs"[Title/Abstract]) OR "Herbal"[Title/Abstract]) OR "herbals"[Title/Abstract]) OR
19 "TCM"[Title/Abstract])) AND (((((((("medicine, chinese traditional"[MeSH Terms] OR
20 "chinese medicine"[Title/Abstract]) OR "traditional chinese medicine"[Title/Abstract]) OR
21 "herbal medicine"[Title/Abstract]) OR "chinese traditional"[Title/Abstract]) OR "chinese
22 herbal"[Title/Abstract]) OR "oriental traditional"[Title/Abstract]) OR "herb"[Title/Abstract])
23 OR "herbs"[Title/Abstract]) OR "Herbal"[Title/Abstract]) OR "herbals"[Title/Abstract]) OR
24 "TCM"[Title/Abstract]) OR (((((((("Acupuncture"[MeSH Terms] OR "acupuncture
25 therapy"[MeSH Terms]) OR "acupuncture treatment*"[Title/Abstract]) OR "treatment
26 acupuncture"[Title/Abstract]) OR "therapy acupuncture"[Title/Abstract]) OR
27 "pharmacoacupuncture treatment"[Title/Abstract]) OR (((((((("therapeutics"[MeSH Terms]
28 OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH
29 Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All
30 Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture
31 therapy"[Title/Abstract]) AND "randomized controlled trial"[Publication Type]))
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Developing a Core Outcome Set on Traditional Chinese Medicine (COS-TCM) for Chronic Heart Failure (CHF): A study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-047148.R1
Article Type:	Protocol
Date Submitted by the Author:	17-Mar-2021
Complete List of Authors:	Zhang, Mingyan; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Chua, Hui Zi; Tianjin University of Traditional Chinese Medicine, Evidence-based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Niu, Bohan; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Zheng, Wenke; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Li, Kai; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Zhang, Junhua; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Zhang, Boli; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center
Primary Subject Heading:	Research methods
Secondary Subject Heading:	Cardiovascular medicine, Complementary medicine
Keywords:	Heart failure < CARDIOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Herbal medicine < THERAPEUTICS



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open: first published as 10.1136/bmjopen-2020-047148 on 2 July 2021. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Developing a Core Outcome Set on Traditional Chinese Medicine (COS-TCM) for Chronic
4 Heart Failure (CHF): A study protocol
5

6 Mingyan Zhang^{1,2#}, Hui Zi Chua^{1,2#}, Bohan Niu^{1,2}, Wenke Zheng^{1,2}, Kai Li^{1,2},
7 Junhua Zhang^{1,2*}, Boli Zhang²
8
9

10
11 1 Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine,
12 Tianjin 301617, China
13

14
15 2 Chinese Clinical Trials Core Outcome Set Research Centre, Tianjin 301617, China
16

17 # These authors contributed equally to the manuscript.
18

19 *Correspondence:
20

21
22 Junhua Zhang, Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese
23 Medicine (e-mail: zjhtcm@foxmail.com).
24
25
26
27
28
29
30
31
32

33 **ABSTRACT**
34

35 **Introduction** Chronic heart failure (CHF) is a serious and advanced stage of various
36 cardiovascular diseases and portends poor prognosis. An increase in clinical studies has
37 reported the effectiveness of traditional Chinese medicine (TCM). For example, intravenous
38 Chinese medicine can significantly improve cardiac function and biomarkers in CHF patients.
39 However, there exists inconsistency, lack of practicality and unclear reporting of outcomes in
40 these clinical trials causing difficulty in the comparison of results across similar studies
41 during data synthesis. A core outcome set (COS) can help in the standardization of outcomes
42 reported across studies from the same healthcare area. The aim of this study is to develop a
43 COS on TCM for CHF (COS-TCM-CHF) to reduce heterogeneity in reporting and improve
44 quality assessment in clinical trials to support data synthesis in addressing the effectiveness
45 of TCM treatment.
46
47
48
49
50
51
52
53

54
55 **Methods and analysis** This study will include constructing an outcome pool which will
56 identify potential outcomes through systematic reviews of TCM RCTs, 2 clinical registry
57 databases, semi-structured interviews of patients and the clinicians' questionnaire. According
58
59
60

1
2
3 to the characteristics of TCM and a taxonomy recommended by the Core Outcome Measures
4 in Effectiveness Trials (COMET) initiative, all outcomes in the outcome pool will be
5 classified into different domains. A preliminary list of outcomes which will then be used in
6 the Delphi survey is generated using a certain criteria based on the length of the pool. The
7 Delphi survey will include two rounds with 7 key stakeholder groups to select candidate
8 items for a consensus meeting. A final COS-TCM-CHF will be developed at a face-to-face
9 consensus meeting involving representatives from the different stakeholders.

16 **Ethics and dissemination** Ethical approval of this study has been granted by Evidence-
17 based Medicine Centre of Tianjin University of Traditional Chinese Medicine Research
18 Ethics Committee (TJUTCMEC201200002). We will disseminate our research findings of
19 the final COS on the website of Chinese Clinical Trials for Core Outcome Set (ChiCOS),
20 with open access publications and present at international conferences to reach a wide range
21 of knowledge users.

28 **Trial Registration number** This study is registered with the COMET initiative study 1486
29 (available at <http://www.comet-initiative.org/studies/details/1486>).

32 **Keywords** chronic heart failure, core outcome set, methodology, traditional Chinese
33 Medicine

38 **Strengths and limitation of this study**

- 41 ◆ Systematic reviews for RCTs in CHF on TCM and identifying additional potential
42 outcomes from 2 clinical trial registry databases (an international-based and a China-
43 based)
- 46 ◆ Semi-structured interviews will involve both patients, as well as clinicians, serving as a
47 qualitative method in the COS development
- 50 ◆ Limiting the preliminary checklist of outcomes to a minimum of 100 items to avoid low
51 response efficiency in the Delphi survey
- 54 ◆ The Delphi survey and consensus meeting will include key stakeholders such as patient
55 representatives, healthcare professionals and COS users.

- ◆ TCM is mainly used in China. Hence, the geographical spread of the representatives of stakeholders will be a limitation but able to address the perspective of Chinese population.

INTRODUCTION

Background

Chronic heart failure, caused by changes in cardiac structure and function, is a serious condition in the advanced stages of various cardiovascular diseases, with a poor prognosis [1]. The prevalence of CHF is rising with an aging population and changes lifestyle habits. It is anticipated that the prevalence of heart failure (HF) will increase 46% from 2012 to 2030, with an estimate of more than 8 million adults with HF in United States [2]. China has an incidence rate of approximately 0.9% in HF [3], with 500,000 new HF patients being diagnosed every year and five year mortality rate as high as 60%-80% [4]. Currently, renin-angiotensin-aldosterone system (RAAS) inhibition, β -receptor blockers, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blocker (ARB) have been the mainstream of medical therapy for CHF [5]. However, prolonged uses of these drugs may cause severe side effects and could result in declining quality of life for CHF patients. Traditional Chinese Medicine (TCM) is commonly used in combination with conventional therapy to treat CHF in China, improving clinical symptoms and health status on the premise of long-term survival.

Syndrome differentiation is used as a treatment principle for TCM, whereby the TCM syndrome exhibits the severity and stages of the disease combining with the patient's constitution. It is determined by using the four methods of diagnosis: tongue examination, history taking (inquiry), listening and smelling examination, palpation (pulse taking, abdominal examination, etc.). Based on the different syndromes of a disease, a combination of herbs or a TCM formula (containing complex compounds in specific ratios and doses) will be used for the treatment. Early intervention of TCM may reduce the adverse effects due to long term usage of conventional drugs, as well as improving the immune and physical function of the patients to minimize re-hospitalization caused by acute attacks of CHF [6]. Clinical studies have reported the effectiveness of TCM such as Qishen Yiqi dripping pills, Shenfu or Shengmai injection can also significantly improve the cardiac function and biomarkers in CHF patients [7]. However, these results should be viewed with caution due to

1
2
3 a lack of methodological quality for TCM related clinical studies. There is inconsistency in
4 the outcomes collected and reported across these studies making it difficult to combine and
5 compare results during systematic reviews and meta-analyses [8]. In addition, these outcomes
6 may lack relevance to patients and clinicians, leading to research waste.
7
8
9

10
11 A way to address this problem of heterogeneity in outcomes reporting is to standardize
12 outcomes reported across CHF-TCM studies, so that outcomes can be meaningful for
13 patients, healthcare professionals and other relevant stakeholders. This could be achieved by
14 the development and implementation of a core outcome set (COS). A COS is an agreed
15 standardized set of outcomes, which should be measured and reported, as a minimum, in all
16 trials for the same healthcare area [9]. The role of developing a COS is to improve the
17 consistency in outcome reporting and to measure appropriate and important outcomes in
18 healthcare trials. A significant increase in registered COS studies on Core Outcome Measures
19 in Effectiveness Trials (COMET) website reflected the increasing awareness of the
20 unwarranted variation in outcome collection and reporting [10]. However, it is worthy to note
21 that the purpose of a standardized outcome set, or COS is not to create new outcomes, but to
22 select those outcomes which matter the most to the various stakeholders such as clinicians,
23 researchers, policy makers and patients.
24
25
26
27
28
29
30
31
32
33

34 In China, there is increasing emphasis on the development of TCM for chronic disease
35 care and prevention, with an increased usage of TCM related interventions on chronic
36 diseases, particularly in heart disease, stroke, cancer and diabetes [11]. This is reflected by
37 the uniqueness of TCM in its ability to treat patients by altering their “inner environment” or
38 simply, to regulate as a whole in the form of improving the patient’s physical function, self-
39 adaptive ability and immune function, which is beneficial for chronic diseases management
40 and prevention. With more research on TCM being carried out in China, guidance to improve
41 the value of trials and provide strong evidence to evaluate the true effectiveness of TCM
42 treatments is urgently required.
43
44
45
46
47
48
49

50 At present, there are two related COSs for HF recorded in the COMET database. The
51 Heart Failure Association of the European Society of Cardiology (HFA-ESC) developed a
52 consensus for HF endpoints in clinical trials published in 2013, with a 1 year follow up on the
53 defined outcomes across different regions between May 2011 and April 2013, reflecting on
54 the higher rate for all-cause mortality in acute HF than CHF across the 1 year span [12-13].
55 Another was the 17-item standardized set of outcome measurement for HF established by
56
57
58
59
60

1
2
3 The International Consortium for Health Outcomes Measurement (ICHOM) on March 2020,
4 which selectively addressed functional, psychosocial, burden of care, and survival outcome
5 domains [14]. Though the stakeholders involved in the COS development for HF represented
6 an international perspective and included patient-reported outcomes, the standardized
7 outcome set in both COSs may be biased toward Western patient populations, lacking
8 engagement in the Chinese patient population and Chinese healthcare professionals, and does
9 not involve any outcomes related to TCM syndromes or its characteristics. Therefore, it is
10 important to develop a COS that specifically address the need of CHF studies using TCM
11 treatment, which can represent all stakeholders for this specific intervention. The COS will
12 include outcomes with TCM characteristics and achieve consensus in Chinese research or
13 clinical experts and its patient population.
14
15
16
17
18
19
20
21
22

23 **Objective**

24
25 Currently, there is no study on COS development for CHF in TCM related clinical studies.
26 The objective of this study is to develop a COS-TCM for CHF (COS-TCM-CHF) and this
27 study protocol is written with reference to the Core Outcome Set-STAndards for Reporting
28 (COS-STAR) [15], the Core Outcome Set-STAndards for Development (COS-STAD) [16]
29 and the Core Outcome Set-STAndardised Protocol Items (COS-STAP) statement [17].
30
31
32
33
34
35

36 **Scope**

37
38 The health condition for this study is on CHF. CHF patients aged 18 and above will be
39 included. This COS will cover all TCM related interventions, including herbal medicine
40 decoction, Chinese patent medicine, extracts of herbal medicine, intravenous Chinese
41 medicine, acupuncture, cupping, Tuina, moxibustion and other rehabilitation therapy of
42 TCM. The COS-TCM-CHF will be implemented in all future studies that examine outcomes
43 of TCM related interventions for CHF.
44
45
46
47
48

49 **Registration**

50
51 This COS study has been registered on the COMET website (study 1486, available at
52 <http://www.comet-initiative.org/Studies/Details/1486>)
53
54
55
56

57 **METHODS AND ANALYSIS**

58
59
60

Steering committee membership

The steering committee will include 10 members, who are experts from different research fields. They include 3 TCM and 3 Western medicine clinical experts in the field of cardiology, 2 methodologists, 1 journal editor, 1 COS developer and 1 patient representative with CHF. The steering committee will review this protocol and provide guidance at each stage of the study process, as well as resolving any disagreements during the process. The committee will also attend and facilitate the consensus meeting as well as to engage COS uptake in the post development stage. All members of the steering committee membership will be co-authors of the COS-TCM-CHF.

Working group

The working group will be made up of 15 members, including TCM and Western medicine clinicians, methodologists, as well as professors and postgraduates from Chinese Clinical Trials COS Research Centre (ChiCOS), Tianjin University of TCM (TJUTCM), China. The role of the working group will include organising regular meetings, facilitating communication and hold discussion meetings to seek advice from the Steering committee if there are any differences to be resolved.

Stakeholders involvement

We will invite 7 groups of stakeholders to participate in the development of COS-TCM-CHF, which include healthcare professionals, patients or their representatives, COS developers, COS users (clinical trialists, systematic reviewers and clinical guideline developers), methodologists, policy makers and journal editors. The recruitment of stakeholders is as follows:

1. Western medicine and TCM healthcare professionals specialising in cardiology, with at least 5 years of clinical experience and academic qualifications of postgraduate and above. They will be selected from the China Association of Chinese Medicine (CACM) and Chinese Society of Cardiology (CSC).
2. Patients diagnosed with CHF possessing a moderate level of literacy and communication from inpatient wards and outpatient clinics of 4 TJUTCM affiliated hospitals.

3. COS developers, especially with relevant TCM experience via searching published or ongoing COS studies registered on COMET website.
4. Methodologists, COS users and journal editors will be invited by sampling with the help of the Chinese Cochrane Centre and TJUTCM Evidence-Based Medicine (EBM) Research Centre.
5. Policy makers in public health decision will be selected by CACM.

Patient and public involvement

Patients or their representatives will be involved in the semi-structured interviews, two rounds of Delphi survey and the final consensus meeting. We will recruit patients or their representatives with adequate communication skills. Addressing outcomes that are important to patients is crucial for COS-TCM-CHF development, hence patients' experiences in the management of CHF will contribute to a large extent in the development process.

Design

The study design for COS-TCM-CHF has been informed by COMET Initiative Handbook, with reference to the guidelines from COS-STAD recommendations and COS-STAP, which will be conducted in five stages (Fig.1):

1. Identifying potential outcomes and constructing an outcome pool. (Stage 1)
2. Merging outcomes and grouping under outcome domains (Stage 2)
3. Generating a preliminary list of outcomes. (Stage 3)
4. Conducting a 2-round Delphi survey to select candidate items for consensus meeting. (Stage 4)
5. Hold a consensus meeting to determine the final COS-TCM-CHF. (Stage 5)

Stage 1 Identifying potential outcomes and constructing an outcome pool

The purpose of COS development is not to create new outcomes, but to identify the most important outcomes to healthcare professionals, researchers, patients and public health decision makers in a specific healthcare field or disease, through a consensus process. We will identify potential outcomes by constructing an outcome pool for COS-TCM-CHF development through the four methods:

1. Conducting systematic review to collect currently reported outcomes from published literature in TCM related clinical studies for CHF.
2. Identifying potential outcomes reported in international and Chinese clinical trial registry databases.
3. Patients' semi-structured interviews to collect outcomes which matter most to the patients or their representatives.
4. Clinicians' questionnaire survey to collect outcomes which are of interest to the healthcare professionals

Method 1: Systematic review of published literature

Search Strategy

We will conduct a comprehensive search strategy from 9 English and Chinese databases. 4 English databases include PubMed, the Cochrane Library, Embase and Web of Science and 5 Chinese databases include China National Knowledge Infrastructure (CNKI), WanFang Database (WanFang), SinoMed, Chinese Scientific Journal Database (VIP) and TCM Clinical Evidence Database System (EVDS-TCM). Randomized clinical trials (RCTs) of CHF with TCM related interventions published in from 2015 to 2020 will be included. The search strategy for English database is shown in Supplementary file 1.

Eligibility criteria

The inclusion and exclusion criteria for the systematic review of published literature is shown in Table 1.

Table 1 Inclusion and Exclusion criteria of the systematic review for published literature

	Inclusion criteria	Exclusion criteria
Types of literature	Randomized controlled trials	Unable to retrieve full texts
Participant	Patients diagnosed with CHF*, above 18 years of age	Patients with other comorbidities or in a more critical condition

Intervention	<ul style="list-style-type: none"> Intervention in treatment group: TCM related treatments which include oral or intravenous herbal medication, Chinese patent medicine, acupuncture, Tuina and acupoint application. Intervention in control group: No limitation 	None
Outcomes	No restriction	No reported outcomes
Language	Chinese and English	Published in Chinese non-core journals

*According to "Guidelines for the diagnosis and treatment of Heart failure in China (2018)" or "American College of Cardiology/American Heart Association (ACC/AHA) guidelines (2016)"

Literature screening and data extraction

Two reviewers will independently screen the literature, extract data and cross-check them according to the inclusion and exclusion criteria. For the missing information of some studies, we will try our best to contact the relevant authors to provide them. If not possible, the study will be excluded. Any disagreements will be resolved through discussion after a thorough reading of the paper or by consulting with the third researcher. An extraction table will be designed by the working group to collect relevant information on the study design, setting, demographics of participants, types of intervention and outcomes. Data extracted on the outcomes reported will include the name, definition, measurement timepoints and measurement instruments or methods. Four principles of data extraction are as follows:

1. Data extracted will be performed by two reviewers which will then be compared and cross-checked. Any disagreements will be resolved by a senior researcher.
2. Outcomes extracted will be reported verbatim to ensure authenticity and traceability from the original data.
3. The free-text field is placed in the extraction table to record special circumstances at any time.

4. Any alteration of the data extracted during the process will be recorded.

Furthermore, we will assess the reporting quality of outcomes reported in the included studies. The method of this assessment is shown in Table 2 with reference to other COS studies [18-20].

Table 2 Seven items assessment of the reporting quality of outcome measures

No.	Criterion	Yes	No
1	Whether the outcome was clearly stated as primary or secondary outcome.	1 point	0 point
2	Whether the outcome was defined or not. Outcomes were considered defined if text of their meaning or a citation was provided.	1 point	0 point
3	It was clearly described how the outcomes are measured or the outcome measurement (indicators and/or tools used, if relevant).	1 point	0 point
4	It was clearly described by whom the outcomes are measured.	1 point	0 point
5	It was clearly described the time points and time period at or during which outcome was measured.	1 point	0 point
6	Are methods used to enhance the quality of outcome measurement (for example, repeated measurement, training) if appropriate?	1 point	0 point
7	The reporting of outcomes was consistent throughout the article. There is no unambiguous reporting that makes it confusing for the reader to assess what has been done.	1 point	0 point

Method 2: International and Chinese clinical trial registry databases

We will search Chinese Clinical Trial Registry (ChiCTR) and Clinical trials.gov registry using the key word “heart failure” from inception to 2020. The protocols registered of CHF RCTs with TCM interventions will be included with reference to the same inclusion and exclusion criteria listed in Table 1. For literature screening and data extraction of clinical trial registration protocols, similar technique will be applied as per the above-mentioned systematic review of published literature. Subsequently, data extracted will be analysed and outcomes will be aggregated with the list of potential outcomes derived from systematic review of published literature, patients’ semi-structured interviews and clinicians’ questionnaire surveys (as described in Method 3 and 4 later). Additionally, the reporting

1
2
3 quality of outcome measures from registered clinical studies will also be assessed using the
4 quality assessment score in Table 2.
5
6

7 **Method 3: Patients' semi-structured interview**

8 *Participant selection and recruitment*

9
10
11
12
13 Patients ≥ 18 years of age, diagnosed with CHF (according to the clinical guidelines for the
14 diagnosis and treatment of chronic heart failure in China or "American College of
15 Cardiology/American Heart Association (ACC/AHA) guidelines 2016") previously or
16 currently under TCM treatment as well as their family members or caregivers will be invited
17 to participate in the semi-structured interview. Potential participants will be approached at the
18 cardiology department of inpatient wards and outpatient clinics in Grade 3A TJUTCM
19 affiliated First Hospital and TJUTCM affiliated Second Hospital, Grade 2A TJUTCM
20 affiliated Fourth Hospital, as well as TJUTCM affiliated BaoKang Community Hospital.
21 Patients or their representatives should possess a moderate level of literacy and
22 communication skills to ensure effective communication. Patients who are cognitively
23 impaired or have serious comorbidities will be excluded from the study. Informed consent is
24 necessary to recruit participants into this study. All potential participants will be informed by
25 a member of the research team, that they are under no obligation to take part and are free to
26 withdraw from the study at any time without their medical care or legal rights being affected.
27 In the event whereby the recruited patients have a language or communication barrier, they
28 will be represented by their caregivers.
29
30
31
32
33
34
35
36
37
38
39
40
41

42 *Sampling size*

43
44
45 Patients' perspective is important and essential throughout the development process.
46 Sampling for qualitative interviews should aim for a diversity of participants [21]. We will
47 consider the gender, age, CHF classification and treatment history of the potential
48 participants. As there is no guideline or consensus on the sample size of this qualitative
49 research, and with past experience of semi-structured interviews done in COS studies [22,23],
50 we aim to recruit a sample size of 50 patients.
51
52
53
54
55

56 *Data collection*

1
2
3 The semi-structured interview will be conducted by qualified and trained investigator to
4 explain the study to the participants. Study information sheets will be given to participants
5 and informed consent will be collected before interviews are commenced. A questionnaire in
6 Chinese language will be designed in advance for this semi-structured interview. A medical
7 history and additional socioeconomic and demographic information on all participants will be
8 collected. The investigator will ask the participants what outcomes are of importance to them
9 in a face-to-face interview. In the event where a participant is not able to answer, the trained
10 investigator will provide the list of outcomes collected from the systematic review of
11 published literature and registered studies as a guide to inform participants on outcomes. In
12 addition, an open-ended question will be asked to allow participants provide any other
13 outcome which they consider important. The interviewer will then populate the questionnaire
14 with the participant's answer. All interviews will be audio-recorded to aid detailed data
15 analysis.

16
17 As the educational level of participants may vary, the questionnaires will be written using
18 plain English or spoken Chinese for ease of understanding. The working group will carry out
19 pilot-testing to establish if the questionnaire is user friendly. Where possible, professional
20 jargon will be changed into plain English or spoken Chinese to ease comprehension for
21 participants. The outline of the semi-structured interview is as listed below:

- 22 1. "What kind of result from the CHF treatment do you think is the most important to you?"
- 23 2. "What is the change in your CHF management, symptoms or daily lifestyle do you
24 consider to be the most important in helping you to determine the effectiveness of the
25 treatment?"
- 26 3. "Which aspect of CHF treatment is of most concern to you or which aspects do you hope
27 to get better improvement?"
- 28 4. "After the treatment for CHF, what changes have made you feel better?"

29 **Method 4: Clinicians' questionnaire survey**

30 *Participant selection and recruitment*

31 Healthcare professionals, including TCM and western practitioners specialising in cardiology
32 with ≥ 5 years of clinical experience and a master's degree or above will be invited to
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 participate in the questionnaire surveys. Potential candidates will be approached at hospital
4 wards and outpatient clinics of TJUTCM affiliated First Hospital, TJUTCM affiliated Second
5 Hospital, TJUTCM affiliated Fourth Hospital and TJUTCM affiliated BaoKang Community
6 Hospital, TJUTCM affiliated Fourth Hospital and TJUTCM affiliated BaoKang Community
7 Hospital. Participation will be on a voluntary basis and informed consent is required if they
8 agreed to participate in the survey.
9

10 11 12 ***Sampling size***

13
14
15
16 Though the outcomes collected will be more comprehensive if the sample size is larger, we
17 considered the feasibility and representativeness of the surveys. Generally, sampling in
18 qualitative studies is purposive, therefore the clinicians who will participate should range
19 from medical officers to senior experts in the field of cardiology. There is currently no
20 guideline for the sampling size for qualitative studies, hence based on our past experience and
21 previous COS studies, we will recruit a sample size of 80 participants. In the event when less
22 than 80 surveys are completed, there will be a further recruitment of clinicians from national
23 cardiology academic conferences until the sample size is reached.
24
25
26
27
28
29

30 31 **Data collection**

32
33
34 A predesigned questionnaire in paper form will be distributed to the healthcare professionals
35 or clinicians. Demographics information, educational and academic status of the clinicians
36 will be collected upon agreement to complete the questionnaire survey. Questionnaires are
37 being designed in an open-ended format and clinicians will have the freedom to fill in
38 outcomes which are of importance to them. There will be a limit to a maximum of 5
39 outcomes listed in order to achieve the selection of outcomes which are of high importance to
40 the clinicians. The list of outcomes collected from the questionnaires will be analysed by the
41 working group.
42
43
44
45
46
47

48 49 **Data analysis**

50
51
52 Data analysis will be performed after collecting data from the 4 different methods. Outcomes
53 collected from literature or clinical registry databases as well as qualitative research (patients'
54 semi-structured interviews and clinicians' questionnaire surveys) will be imported into an
55 Excel table. These outcomes collected will form the outcome pool. The outcomes will be
56 labelled with numbers corresponding to the original studies or qualitative surveys for easy
57
58
59
60

1
2
3 reference and traceability. Upon completion of outcome labelling, the outcomes will then be
4 cross-checked and standardized. The methods of standardizing outcomes are as follows:
5
6
7

- 8 1. The outcomes are sorted according to their similarities.
- 9
10 2. Extracted verbatim of the outcomes will be standardized according to their original
11 description or definition, in order to address problems such as abbreviations, nicknames and
12 composite outcomes. The composite outcome will be separated into individual outcomes.
13
14 3. Duplicates will be removed from the outcome pool. Similar and overlapping outcomes will
15 be merged into their standardized terminologies.
16
17 4. Two researchers of the working group will record the corresponding number assigned to
18 the outcomes in the list as well as record the frequency of each outcome.
19
20
21
22
23
24

25 Finally, an outcome pool is constructed after the outcomes are standardized. The steering
26 committee will be consulted if there were any discrepancies in the process of outcome
27 standardization. And if there is no consensus reached on an outcome, the outcome will be
28 excluded.
29
30
31

32 **Stage 2 Merging outcomes and grouping under outcome domains**

33
34 After an outcome pool is constructed, outcomes will be merged and grouped under their
35 respective outcome domains recommended in previous COS studies [24]. Since COS-CHF-
36 TCM focuses on developing a set of outcomes to be implemented in TCM related studies, the
37 outcome classification with TCM characteristics will be added such as TCM syndrome
38 scoring scale. The process will be carried out by two researchers independently. After which
39 the classification of outcomes will be cross-checked. Any discrepancies will be resolved by a
40 third researcher from the steering committee.
41
42
43
44
45
46
47

48 **Stage 3 Generating a preliminary list of outcomes**

49
50 The outcome pool can be used as a preliminary list of outcomes in the questionnaire of the
51 Delphi process. However, this list of outcomes can be a long list. If the list of outcomes from
52 the outcome pool is directly taken as the preliminary list of outcomes, it may result in a low
53 response during Delphi survey. Based on previous experience in developing a COS,
54 participants involved in the Delphi survey were less willing to respond when there was a
55 large number of outcomes in the preliminary list, for instance needing more than 10 minutes
56
57
58
59
60

1
2
3 to complete the questionnaire. Furthermore, the scores of outcomes are likely to be too
4 concentrated, making it difficult to reach a consensus on the ranking of importance. As a
5 result, multiple rounds of Delphi survey will be required which lead to additional time and
6 resource wastage.
7
8
9

10 Therefore, it is important to shorten the list of outcome pool to establish a preliminary list of
11 outcomes, which of a suitable length to be used in the Delphi survey later (Stage 4). The
12 criteria for retaining or dropping the outcomes are as follows:
13
14

- 15 1. If the number of outcomes collected in the outcome pool is less than or equal to 100, all
16 outcomes will be retained in the preliminary list.
17
- 18 2. If the number of outcomes collected in the outcome pool is more than 100, the working
19 group will conduct an internal vote to drop the items in the outcome pool under the guidance
20 of the steering committee. If 90% of the members in the working group think that an item is
21 unnecessary to enter the preliminary list, the item will be removed. The remaining items will
22 then be included to form the preliminary list of outcomes.
23
24
25
26
27
28

29 **Stage 4 2-round Delphi survey**

30 *Software*

31
32 The 2-round electronic Delphi survey will be conducted using a Delphi software developed
33 by ChiCOS, similar to the DelphiManager software implemented by COMET working group
34 for COS research. The Delphi software is programmed using Chinese language to cater to the
35 stakeholder groups in China. According to the preliminary list of outcomes, it can
36 automatically generate questionnaire for the Delphi survey and to display results of outcome
37 scoring from the participants and comparison over different stakeholder after each round of
38 survey is completed. The Delphi software is also equipped with a database containing the
39 information of pre-existing Delphi participants or experts shared by ChiCOS working group.
40
41
42
43
44
45
46
47
48

49 *Selection of Delphi participants and sampling size*

50
51 Seven stakeholder groups will be invited to participate in the Delphi survey, which include
52 clinicians, CHF patients or their representatives, experienced COS developers,
53 methodologists, potential COS users (clinical trialists, systematic reviewers, clinical guideline
54 developers, etc.), policy makers and journal editors. The 3 key stakeholder groups as
55 mentioned in COS-STAD, namely the clinicians, patients or their representatives and COS
56
57
58
59
60

1
2
3 users are essential in COS development. Hence, we will invite at least 40 participants for
4 each of the 3 key stakeholder groups. For the group of clinicians, a 1:1 ratio will be fixed for
5 Western medicine doctors and TCM doctors. At least 15 participants will be invited for each
6 of the remaining stakeholder groups. We plan to invite approximately 210 participants for the
7 Delphi survey. It is beneficial for more participants to represent each stakeholder group in
8 order to convince future patients or other stakeholders of its value. Hence, there is no need to
9 specify an upper limit for the number of participants. The selection criteria for participants
10 from the different stakeholders was previously stated in the “Stakeholders involvement”
11 section. Relevant information of the selected participants (excluding patients) will be
12 recorded in the Delphi experts’ database system on ChiCOS website. It is noteworthy to
13 identify the pre-existing Delphi participants name list available on Delphi database system on
14 ChiCOS website shared by members of ChiCOS working group as well as other COS
15 developers. This set of name list can be used to supplement the Delphi participants for this
16 study.
17
18
19
20
21
22
23
24
25
26
27

28 ***Delphi scoring***

29
30
31 The Delphi process will require each participant to consider the importance of each outcome
32 from the four aspects, namely importance on clinical value, recognizability of outcomes in
33 related studies, able to reflect the advantages of TCM effectiveness, as well as being
34 consistent and measurable. Participants will be asked to score each of the outcome items in
35 the preliminary checklist using a scoring scale of 1 to 9, with 1 to 3 is labelled as ‘not
36 important’, 4 to 6 labelled as ‘important but not critical’ and 7 to 9 labelled as ‘critical’ [25].
37 Participants will have an option of ‘unsure’ if they are unable to assess the importance of the
38 outcome items.
39
40
41
42
43
44

45 **Delphi round 1**

46
47
48 The preliminary list of outcomes generated in Stage 3 will be used in the first round of Delphi
49 survey. For the questionnaire of Delphi round 1, a brief summary of the COS study will be
50 presented to the participants. Participants will need to select which stakeholder group they
51 belong to and be asked to score all the outcome items. At the end of the questionnaire, there
52 is an additional open question, “What other outcomes do you think are important but not
53 included in this questionnaire?”, to allow participants to add new outcomes. Besides,
54 participants will have the option to provide their suggestion in a free-text field at the end of
55 each item. Upon agreeing to participate in the Delphi survey, participants are required to
56
57
58
59
60

1
2
3 score all outcome items. If the list of questions in the survey is not completed, there will be a
4 reminder to avoid any missing data. Participants will not be able to submit any incomplete
5 questionnaire so as to ensure the integrity of the survey. In order to ensure the
6 comprehensibility of the questionnaire, we will invite a language expert to assist in revising
7 the outcome terminology into plain language. The questionnaire will be pilot-tested on a
8 small group of participants before disseminating to all participants.
9

10
11
12
13
14 Participants (excluding patients) will be sent a personalised email outlining the study along
15 with a link to the online questionnaire of Delphi round 1. And they will be asked to complete
16 the survey within 3 weeks. A reminder email will be sent out at the end of week 2 to prompt
17 completion of the survey. An inspection to assess the number of participants will be done
18 near the end of week 2 by the working group. If the response rate of the Delphi survey
19 (number of respondents / number of invited participants) is lower than 70%, the survey will
20 be extended for 2 more weeks and a reminder email will be sent to the respective participants
21 who did not respond. For the stakeholder group of patients or their representatives, the survey
22 will be conducted face-to-face in inpatient wards or outpatient clinics by a trained
23 investigator to complete the paper questionnaire. Both the online and paper questionnaires are
24 of the same version. All participants are asked to score each item according to their
25 importance. After completing the rating score, they will have the opportunity to add any other
26 item which is not in the list but important to them.
27

28
29
30
31
32
33
34
35
36
37 The working group will collect all completed questionnaires and calculate the overall
38 participant response rate for Delphi round 1. For each outcome item, the average score, the
39 score distribution across different stakeholder groups as well as the number of participants
40 from different stakeholders who have scored it will be summarized. If $\geq 70\%$ of the
41 participants in any stakeholder group considered the item to be “important” or “critical” (ie.
42 score of 4-9 points), the item will be included in the next round of Delphi. At the same time,
43 the working group will inspect and determine whether the newly added items by the
44 participants are duplicates in the preliminary list and only new and unique outcome will be
45 retained to be included in the next round for scoring. Duplicates or overlapping outcomes will
46 be removed and not enter the next round.
47
48
49
50
51
52
53

54 55 **Delphi round 2**

56
57
58 Participants who completed the first round will be invited to participate in Delphi round 2.
59 Response rate, the distribution of scores and participants' own score for each outcome are
60

1
2
3 being presented to all participants. After considering the feedback from the first round,
4 participants will be asked to re-score the retained outcomes which have met the requirement
5 to enter the second round and score the newly added outcome items from the first round. If
6 the scores between the two rounds change drastically, for example a participant considered an
7 item in round 1 as “not important” (1-3points) and rescores the item as “critical” (7-9 points)
8 in round 2, he or she will need to provide the reason for the change in scores in the free-text
9 field. Participants are also able to provide any suggestions for each item in the survey.

10
11
12
13
14
15
16 Delphi round 2 survey will also be sent out electronically to all participants (excluding
17 patients or their representatives) by the Delphi software developed by ChiCOS. The survey
18 will be printed into hard copy similar to Delphi round 1 for patients to complete in the second
19 round. The survey should be completed within 3 weeks and a reminder email will be sent to
20 prompt completion of the survey at the end of week 2. If the response rate is lower than 70%,
21 the survey will be extended for 1 more week and a reminder email will be sent to the
22 respective participants who did not respond.

23
24
25
26
27
28
29 At the end of Delphi round 2, the participants’ response rate, the average score as well as the
30 score distribution for each outcome item are calculated. Participants’ score changes between
31 round 1 and 2 will be examined and verified, as well as summarizing the reasons for the
32 change in scores. Together with the reasons, the average score for each outcome in round 2 is
33 compared with that in round 1, so that we can assess attrition bias. There will not be any
34 source for missing data as we have made it compulsory for participants to complete all the
35 questions in the Delphi survey before submission.

41 **Stage 5 Consensus meeting**

42
43
44 The final phase of the developing COS-TCM-CHF is to hold a face-to-face consensus
45 meeting after the Delphi process. The consensus meeting will be a one day event and 35
46 participants will be invited to confirm the final outcomes for COS-TCM-CHF. The consensus
47 meeting will be held in Tianjin, China for the convenience of most participants. In the event
48 where there are other major events such as the resurgence of Coronavirus outbreak, the
49 meeting will be changed to online video conference.

54 **Recruitment**

55
56
57 We will invite participants from the different stakeholder groups who have completed the two
58 rounds of Delphi survey to join the consensus meeting. Experts of the steering committee and
59
60

members of the working group will also attend the meeting. We will draw lots to select representatives of the participants from each stakeholder group, including patient participants. If a representative from a stakeholder group is not available to attend the meeting, he or she will be replaced by another participant from the same stakeholder group.

Consensus definition

Consensus criteria will be specified a priori. The definition of the consensus is shown in Table 3, which was made according to the consensus previously used by other COSs developed and COMET recommendations [9,21,26]. Outcomes are classified into 3 categories: ‘consensus in’, ‘consensus out’ and ‘no consensus’.

Table 3 Consensus definition		
Consensus classification	Description	Definition
Consensus in	Consensus that outcome should be included in COS	>70% of participants scoring 7-9 and <15% of participants scoring 1-3
Consensus out	Consensus that outcome should not be included in the COS	>70% of participants scoring 1-3 and <15% of participants scoring 7-9
No consensus	Uncertainty about importance of the outcome	Anything else

Consensus process and final decisions

After a short review of the COS-TCM-CHF study, the scoring results of Delphi round 2 will be shown to all participants in the meeting. According to the consensus definition, outcomes of “consensus in” will be prioritised to be included in the final COS and outcomes of “consensus out” will be excluded. The participants will vote anonymously for the outcomes rated as “no consensus”. After the voting, results will be calculated and outcomes achieving a consensus will enter the final COS-TCM-CHF. In the process, all participants have the opportunity to discuss any outcome. If there are any disputes, it will be settled by the Steering committee through the nominal group technique (NGT) [27]. The final COS-TCM-CHF will be developed which will include 4-10 core outcomes according to the COMET recommendations [21].

Fig. 1 Flow chart of the study design for COS-TCM-CHF

List of abbreviations

heart failure (HF), chronic heart failure (CHF), core outcome set (COS), traditional Chinese medicine (TCM), Core outcome set on Traditional Chinese medicine (COS-TCM), Core outcome set on Traditional Chinese medicine for chronic heart failure (COS-TCM-CHF), Heart Failure Association of the European Society of Cardiology (HFA-ESC), The International Consortium for Health Outcomes Measurement (ICHOM), Core Outcome Measures in Effectiveness Trials (COMET), Core outcome set-STANDARDISED Protocol (COS-STAP), reporting guidelines for studies developing COS protocol (COS-STAR), Chinese Clinical Trials COS Research Centre (ChiCOS), Tianjin University of TCM (TJUTCM), Core outcome set-STANDARDS for Development (COS-STAD), randomized clinical trials (RCTs)

Ethics and dissemination

The study has obtained ethical approval through the Ethics Committee of the Evidence-based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Ref: TJUTCMEC201200002. Informed consent will be obtained from all participants who participate in the semi-structured interviews, questionnaire survey and two rounds of the Delphi survey. The study is registered with the COMET Initiative (<http://www.cometinitiative.org/Studies/Details/1486>).

When the development of the COS is completed, it will be reported based on the items of the Core Outcome Set-STANDARDS for Reporting (COS-STAR). The findings will be submitted for publication in peer-reviewed and open access journals and will be presented at national and international conferences on CHF. In addition, the results will be disseminated on the website of Chinese clinical trials of COS (www.Chicos.org.cn). In addition, with the help of ChiCOS and the China association of Chinese medicine, we hope to promote awareness of the COS results and we intend to send the publication of the COS to all participants via emails or express delivery to improve COS-TCM implementation.

Author affiliations

1 Evidence-based Medicine Centre, Chinese Medicine Institute, Tianjin University of Traditional Chinese Medicine, Tianjin, China

1
2
3 2 Chinese Clinical Trials Core Outcome Set Research Centre, Tianjin, China
4
5

6 ***Authors' contributions***
7

8 MZ and HZC wrote the paper and conceived the project. MZ and HZC contributed equally to
9 the manuscript. HZC contributed to the English translation of this protocol. MZ and JZ are the
10 principal investigators of the study, and MZ obtained the support of the National Natural
11 Science Foundation of China. HZC, BN and KL are responsible for conducting the systematic
12 review. WZ and BZ provide supervision for the project. All authors edited and critically revised
13 the study protocol. All authors have read, contributed to and approved the manuscript.
14
15
16
17
18
19

20 ***Funding***
21

22 This work was supported by the National Natural Science Foundation of China
23 (No.81473544).
24
25

26 ***Competing interests***
27

28 All authors declare that they have no competing interests.
29

30 ***Patient and public involvement***
31

32 Patients and/or the public were involved in the design, or conduct, or reporting, or
33 dissemination plans of this research. Refer to the Methods section for further details.
34
35

36 ***Patient consent for publication***
37

38 Not required
39
40

41 ***Provenance and peer review***
42

43 Not commissioned; externally peer reviewed.
44
45

46 ***Open access***
47

48 This is an open access article distributed in accordance with the Creative Commons
49 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,
50 remix, adapt, build upon this work non-commercially, and license their derivative works on
51 different terms, provided the original work is properly cited, appropriate credit is given, any
52 changes made indicated, and the use is non-commercial. See:
53
54

55 <http://creativecommons.org/licenses/by-nc/4.0/>.
56
57

58
59 ORCID iDs
60

1
2
3 Mingyan Zhang <https://orcid.org/0000-0002-4413-7784>

4
5 Hui Zi Chua <https://orcid.org/0000-0003-3927-9179>

6
7 Bohan Niu <https://orcid.org/0000-0002-3092-9879>

8
9 Kai Li <https://orcid.org/0000-0003-2724-338X>

10
11 Wenke Zheng <https://orcid.org/0000-0001-7963-5946>

12
13 Junhua Zhang <https://orcid.org/0000-0003-4043-1967>

14
15
16
17 ***Consent for publication***

18
19 Not applicable

20
21 ***Availability of data and materials***

22
23 Not applicable

24
25
26
27 **References:**

- 28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail.* 2016;18(8):891-975. doi:10.1002/ejhf.592
 2. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation.* 2020;141(9):e139-e596. doi:10.1161/CIR.0000000000000757
 3. R. Ariely et al. Heart Failure in China: A review of literature. *Drugs* 2013, 73(7):689-701.
 4. Jun Huang. Epidemiology characteristics and preventive strategies of heart failure in China. *Chinese Journal of Heart and Rhythm Electronics* 2015,3(2):2-3.
 5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2013
 6. Q Jia, L Wang, X Zhang et al. Prevention and treatment of chronic heart failure through traditional Chinese medicine: Role of the gut microbiota. *Pharmacological Research.* 151 (2020) 104552.
 7. Wang Y, Wang Q, Li C, et al. A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure. *Curr Pharm Des.* 2017;23(34):5115-5124.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
8. Zhang L, Zhang J, Chen J, et al. Clinical Research of Traditional Chinese Medicine Needs to Develop Its Own System of Core Outcome Sets [J]. *Evidence-Based Complementary and Alternat Med*, 2013; 2013:202703.
9. Williamson, P.R., Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider[J]. *Trials*, 2012. 13: p.132.
10. Elizabeth Gargon, Sarah L. Gorst, Paula R. Williamson. Choosing important health outcomes for comparative effectiveness research: 5th annual update to a systematic review of core outcome sets for research[J]. *PLoS ONE* 14(12): e0225980.
11. Fan X, Meng F, Wang D et al. Perceptions of traditional Chinese medicine for chronic disease care and prevention: a cross-sectional study of Chinese hospital-based health care professionals. *BMC Complement Altern Med*. 2018 Jul 6;18(1):209.
12. Zannad F, Garcia AA, Anker SD et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail*. 2013 Oct;15(10):1082-94.
13. Crespo-Leiro MG, Anker SD, Maggioni AP et al. Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail*. 2016 Jun;18(6):613-25. doi: 10.1002/ejhf.566. Erratum in: *Eur J Heart Fail*. 2017 Mar;19(3):438.
14. Burns DJP, Arora J, Okunade O et al. International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients. *JACC Heart Fail*. 2020 Mar;8(3):212-222.
15. Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, et al. (2016) Core Outcome Set–STAndards for Reporting: The COS-STAR Statement. *PLoS Med* 13(10): e1002148.
16. Kirkham JJ, Davis K, Altman DG, et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations[J]. *PLoS Med*, 2017. 14(11): p. e1002447.
17. Kirkham, J.J., Gorst, S., Altman, D.G. *et al*. Core Outcome Set-STANDARDISED Protocol Items: the COS-STAP Statement. *Trials* 20, 116 (2019).
18. Harman NL, Bruce IA, Callery P, et al. MOMENT--Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials*. 2013;14:70
19. Alkhaffaf B, Blazeby JM, Williamson PR, et al. Reporting of outcomes in gastric cancer surgery trials: a systematic review. *BMJ Open* 2018;8:e21796.
20. Heemskerk SCM, Rotteveel AH, Melenhorst J, Breukink SO, Kimman ML, Dirksen CD. Heterogeneous outcome reporting in adult slow-transit constipation studies: Systematic review towards a core outcome set. *J Gastroenterol Hepatol*. 2020;35(2):192–203.
21. Williamson, P.R., Altman, D.G., Bagley, H. *et al*. The COMET Handbook: version 1.0. *Trials* 18, 280 (2017).

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. Tugwell P, Boers M. OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. *J Rheumatol* 1993;20:528–30.
 23. Qiu R, Zhong C, Han S, et al. Development of a core outcome set for myocardial infarction in clinical trials of traditional Chinese medicine: a study protocol. *BMJ Open*. 2019;9(12):e032256.
 24. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *J Clin Epidemiol*. 2018 Apr;96:84-92.
 25. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol*. 2011;64(4):395–400.
 26. de Blacam C, Baylis AL, Kirschner RE, Smith SM, Sell D, Sie KCY, Harris HE, Orr DJA. Protocol for the development of a core outcome set for reporting outcomes of management of velopharyngeal dysfunction. *BMJ Open*. 2020 Aug 13;10(8):e036824. doi: 10.1136/bmjopen-2020-036824. PMID: 32792441; PMCID: PMC7430341.
 27. Wiggins ST, Colby S, Moret L, McElrone M, Olfert MD, Riggsbee K, Opoku-Acheampong A, Kidd T. A Modified Nominal Group Technique (mNGT) - Finding Priorities in Research. *Am J Health Behav*. 2020 May 1;44(3):345-352. doi: 10.5993/AJHB.44.3.7. PMID: 32295682.




Fig. 1 Flow chart of the study design for COS-TCM-CHF

Supplementary File 1

#1 "chronic"[All Fields] OR "chronical"[All Fields] OR "chronically"[All Fields] OR "chronicities"[All Fields] OR "chronicity"[All Fields] OR "chronicization"[All Fields] OR "chronics"[All Fields] AND "heart failure"[MeSH Terms] OR "heart failure"[Title/Abstract] OR "cardiac failure"[Title/Abstract] OR "myocardial failure"[Title/Abstract] OR "cardiomyopath*"[Title/Abstract] OR "cardio renal syndrome"[Title/Abstract] OR "dyspnea paroxysmal"[Title/Abstract] OR "edema cardiac"[Title/Abstract] OR "heart failure diastolic"[Title/Abstract] OR "heart failure systolic"[Title/Abstract] OR "heart decompensation"[Title/Abstract] OR "decompensation heart"[Title/Abstract] OR "heart failure right sided"[Title/Abstract] OR "heart failure right sided"[Title/Abstract] OR "right sided heart failure"[Title/Abstract] OR "right sided heart failure"[Title/Abstract] OR "congestive heart failure"[Title/Abstract] OR "heart failure congestive"[Title/Abstract] OR "heart failure left sided"[Title/Abstract] OR "heart failure left sided"[Title/Abstract] OR "left sided heart failure"[Title/Abstract] OR "left sided heart failure"[Title/Abstract]

#2 "medicine, chinese traditional"[MeSH Terms] OR "chinese medicine"[Title/Abstract] OR "traditional chinese medicine"[Title/Abstract] OR "herbal medicine"[Title/Abstract] OR "chinese traditional"[Title/Abstract] OR "chinese herbal"[Title/Abstract] OR "oriental traditional"[Title/Abstract] OR "herb"[Title/Abstract] OR "herbs"[Title/Abstract] OR "Herbal"[Title/Abstract] OR "herbals"[Title/Abstract] OR "TCM"[Title/Abstract]

#3 "Acupuncture"[MeSH Terms] OR "acupuncture therapy"[MeSH Terms] OR "acupuncture treatment*"[Title/Abstract] OR "treatment acupuncture"[Title/Abstract] OR "therapy acupuncture"[Title/Abstract] OR "pharmacoacupuncture treatment"[Title/Abstract] OR (((((((("therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture therapy"[Title/Abstract]

#4 #2 OR #3 (((((((((((("medicine, chinese traditional"[MeSH Terms] OR "chinese medicine"[Title/Abstract]) OR "traditional chinese medicine"[Title/Abstract]) OR "herbal medicine"[Title/Abstract]) OR "chinese traditional"[Title/Abstract]) OR "chinese herbal"[Title/Abstract]) OR "oriental traditional"[Title/Abstract]) OR "herb"[Title/Abstract]) OR "herbs"[Title/Abstract]) OR "Herbal"[Title/Abstract]) OR "herbals"[Title/Abstract]) OR "TCM"[Title/Abstract]) OR (((((((("Acupuncture"[MeSH Terms] OR "acupuncture therapy"[MeSH Terms]) OR "acupuncture treatment*"[Title/Abstract]) OR "treatment acupuncture"[Title/Abstract]) OR "therapy acupuncture"[Title/Abstract]) OR "pharmacoacupuncture treatment"[Title/Abstract]) OR (((((((("therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture therapy"[Title/Abstract]) AND "randomized controlled trial"[Publication Type])

#5 #1 AND #4 (((((((((((((((((((((((("chronic"[All Fields] OR "chronical"[All Fields]) OR "chronically"[All Fields]) OR "chronicities"[All Fields]) OR "chronicity"[All Fields]) OR

1
2
3 "chronicization"[All Fields]) OR "chronics"[All Fields]) AND "heart failure"[MeSH Terms]
4 OR "heart failure"[Title/Abstract]) OR "cardiac failure"[Title/Abstract]) OR "myocardial
5 failure"[Title/Abstract]) OR "cardiomyopath*"[Title/Abstract]) OR "cardio renal
6 syndrome"[Title/Abstract]) OR "dyspnea paroxysmal"[Title/Abstract]) OR "edema
7 cardiac"[Title/Abstract]) OR "heart failure diastolic"[Title/Abstract]) OR "heart failure
8 systolic"[Title/Abstract]) OR "heart decompensation"[Title/Abstract]) OR "decompensation
9 heart"[Title/Abstract]) OR "heart failure right sided"[Title/Abstract]) OR "heart failure right
10 sided"[Title/Abstract]) OR "right sided heart failure"[Title/Abstract]) OR "right sided heart
11 failure"[Title/Abstract]) OR "congestive heart failure"[Title/Abstract]) OR "heart failure
12 congestive"[Title/Abstract]) OR "heart failure left sided"[Title/Abstract]) OR "heart failure
13 left sided"[Title/Abstract]) OR "left sided heart failure"[Title/Abstract]) OR "left sided heart
14 failure"[Title/Abstract]) AND (((((((("medicine, chinese traditional"[MeSH Terms] OR
15 "chinese medicine"[Title/Abstract]) OR "traditional chinese medicine"[Title/Abstract]) OR
16 "herbal medicine"[Title/Abstract]) OR "chinese traditional"[Title/Abstract]) OR "chinese
17 herbal"[Title/Abstract]) OR "oriental traditional"[Title/Abstract]) OR "herb"[Title/Abstract])
18 OR "herbs"[Title/Abstract]) OR "Herbal"[Title/Abstract]) OR "herbals"[Title/Abstract]) OR
19 "TCM"[Title/Abstract])) AND (((((((("medicine, chinese traditional"[MeSH Terms] OR
20 "chinese medicine"[Title/Abstract]) OR "traditional chinese medicine"[Title/Abstract]) OR
21 "herbal medicine"[Title/Abstract]) OR "chinese traditional"[Title/Abstract]) OR "chinese
22 herbal"[Title/Abstract]) OR "oriental traditional"[Title/Abstract]) OR "herb"[Title/Abstract])
23 OR "herbs"[Title/Abstract]) OR "Herbal"[Title/Abstract]) OR "herbals"[Title/Abstract]) OR
24 "TCM"[Title/Abstract]) OR (((((((("Acupuncture"[MeSH Terms] OR "acupuncture
25 therapy"[MeSH Terms]) OR "acupuncture treatment*"[Title/Abstract]) OR "treatment
26 acupuncture"[Title/Abstract]) OR "therapy acupuncture"[Title/Abstract]) OR
27 "pharmacoacupuncture treatment"[Title/Abstract]) OR (((((((("therapeutics"[MeSH Terms]
28 OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH
29 Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All
30 Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture
31 therapy"[Title/Abstract]) AND "randomized controlled trial"[Publication Type]))
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Developing a Core Outcome Set on Traditional Chinese Medicine (COS-TCM) for Chronic Heart Failure (CHF): A study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-047148.R2
Article Type:	Protocol
Date Submitted by the Author:	13-May-2021
Complete List of Authors:	Zhang, Mingyan; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Chua, Hui Zi; Tianjin University of Traditional Chinese Medicine, Evidence-based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Zhang, Junhua; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Niu, Bohan; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Zheng, Wenke; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Li, Kai; Tianjin University of Traditional Chinese Medicine, Evidence-Based Medicine Centre; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center Zhang, Boli; Tianjin University of Traditional Chinese Medicine, Chinese Clinical Trials Core Outcome Set Research Center
Primary Subject Heading:	Research methods
Secondary Subject Heading:	Cardiovascular medicine, Complementary medicine
Keywords:	Heart failure < CARDIOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Herbal medicine < THERAPEUTICS



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Developing a Core Outcome Set on Traditional Chinese Medicine (COS-TCM) for Chronic
4 Heart Failure (CHF): A study protocol
5

6 Mingyan Zhang^{1,2#}, Hui Zi Chua^{1,2#*}, Junhua Zhang^{1,2*}, Bohan Niu^{1,2}, Wenke
7 Zheng^{1,2}, Kai Li^{1,2}, Boli Zhang²
8
9

10
11 1 Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine,
12 Tianjin 301617, China
13

14
15 2 Chinese Clinical Trials Core Outcome Set Research Centre, Tianjin 301617, China
16

17 # These authors contributed equally to the manuscript.
18

19 *Corresponding Authors:
20

21
22 Junhua Zhang, Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese
23 Medicine (e-mail: zjhtcm@foxmail.com).
24
25

26
27 Hui Zi Chua, Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese
28 Medicine (e-mail: hzchua_tcm@hotmail.com)
29
30
31
32
33
34
35
36
37

38 ABSTRACT

39
40 **Introduction** Chronic heart failure (CHF) is a serious and advanced stage of various
41 cardiovascular diseases and portends poor prognosis. An increase in clinical studies has
42 reported the effectiveness of traditional Chinese medicine (TCM). For example, intravenous
43 Chinese medicine can significantly improve cardiac function and biomarkers in CHF patients.
44 However, there exists inconsistency, lack of practicality and unclear reporting of outcomes in
45 these clinical trials causing difficulty in the comparison of results across similar studies
46 during data synthesis. A core outcome set (COS) can help in the standardization of outcomes
47 reported across studies from the same healthcare area. The aim of this study is to develop a
48 COS on TCM for CHF (COS-TCM-CHF) to reduce heterogeneity in reporting and improve
49 quality assessment in clinical trials to support data synthesis in addressing the effectiveness
50 of TCM treatment.
51
52
53
54
55
56
57
58
59
60

1
2
3 **Methods and analysis** This study will include constructing an outcome pool which will
4 identify potential outcomes through systematic reviews of TCM RCTs, 2 clinical registry
5 databases, semi-structured interviews of patients and the clinicians' questionnaire. According
6 to the characteristics of TCM and a taxonomy recommended by the Core Outcome Measures
7 in Effectiveness Trials (COMET) initiative, all outcomes in the outcome pool will be
8 classified into different domains. A preliminary list of outcomes which will then be used in
9 the Delphi survey is generated using a certain criteria based on the length of the pool. The
10 Delphi survey will include two rounds with 7 key stakeholder groups to select candidate
11 items for a consensus meeting. A final COS-TCM-CHF will be developed at a face-to-face
12 consensus meeting involving representatives from the different stakeholders.
13
14
15
16
17
18
19
20

21 **Ethics and dissemination** Ethical approval of this study has been granted by Evidence-
22 based Medicine Centre of Tianjin University of Traditional Chinese Medicine Research
23 Ethics Committee (TJUTCMEC201200002). We will disseminate our research findings of
24 the final COS on the website of Chinese Clinical Trials for Core Outcome Set (ChiCOS),
25 with open access publications and present at international conferences to reach a wide range
26 of knowledge users.
27
28
29
30
31
32

33 **Trial Registration number** This study is registered with the COMET initiative study 1486
34 (available at <http://www.comet-initiative.org/studies/details/1486>).
35
36
37

38 **Keywords** chronic heart failure, core outcome set, methodology, traditional Chinese
39 Medicine
40
41
42
43

44 **Strengths and limitation of this study**

- 45 ◆ Systematic reviews for RCTs in CHF on TCM and identifying additional potential
46 outcomes from 2 clinical trial registry databases (an international-based and a China-
47 based)
- 48 ◆ Semi-structured interviews will involve both patients, as well as clinicians, serving as a
49 qualitative method in the COS development
- 50 ◆ Limiting the preliminary checklist of outcomes to a minimum of 100 items to avoid low
51 response efficiency in the Delphi survey
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- ◆ The Delphi survey and consensus meeting will include key stakeholders such as patient representatives, healthcare professionals and COS users.
- ◆ TCM is mainly used in China. Hence, the geographical spread of the representatives of stakeholders will be a limitation but able to address the perspective of Chinese population.

INTRODUCTION

Background

Chronic heart failure, caused by changes in cardiac structure and function, is a serious condition in the advanced stages of various cardiovascular diseases, with a poor prognosis [1]. The prevalence of CHF is rising with an aging population and changes lifestyle habits. It is anticipated that the prevalence of heart failure (HF) will increase 46% from 2012 to 2030, with an estimate of more than 8 million adults with HF in United States [2]. China has an incidence rate of approximately 0.9% in HF [3], with 500,000 new HF patients being diagnosed every year and five year mortality rate as high as 60%-80% [4]. Currently, renin-angiotensin-aldosterone system (RAAS) inhibition, β -receptor blockers, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blocker (ARB) have been the mainstream of medical therapy for CHF [5]. However, prolonged uses of these drugs may cause severe side effects and could result in declining quality of life for CHF patients. Traditional Chinese Medicine (TCM) is commonly used in combination with conventional therapy to treat CHF in China, improving clinical symptoms and health status on the premise of long-term survival.

Syndrome differentiation is used as a treatment principle for TCM, whereby the TCM syndrome exhibits the severity and stages of the disease combining with the patient's constitution. It is determined by using the four methods of diagnosis: tongue examination, history taking (inquiry), listening and smelling examination, palpation (pulse taking, abdominal examination, etc.). Based on the different syndromes of a disease, a combination of herbs or a TCM formula (containing complex compounds in specific ratios and doses) will be used for the treatment. Early intervention of TCM may reduce the adverse effects due to long term usage of conventional drugs, as well as improving the immune and physical function of the patients to minimize re-hospitalization caused by acute attacks of CHF [6]. Clinical studies have reported the effectiveness of TCM such as Qishen Yiqi dripping pills,

1
2
3 Shenfu or Shengmai injection can also significantly improve the cardiac function and
4 biomarkers in CHF patients [7]. However, these results should be viewed with caution due to
5 a lack of methodological quality for TCM related clinical studies. There is inconsistency in
6 the outcomes collected and reported across these studies making it difficult to combine and
7 compare results during systematic reviews and meta-analyses [8]. In addition, these outcomes
8 may lack relevance to patients and clinicians, leading to research waste.
9

10
11
12
13
14 A way to address this problem of heterogeneity in outcomes reporting is to standardize
15 outcomes reported across CHF-TCM studies, so that outcomes can be meaningful for
16 patients, healthcare professionals and other relevant stakeholders. This could be achieved by
17 the development and implementation of a core outcome set (COS). A COS is an agreed
18 standardized set of outcomes, which should be measured and reported, as a minimum, in all
19 trials for the same healthcare area [9]. The role of developing a COS is to improve the
20 consistency in outcome reporting and to measure appropriate and important outcomes in
21 healthcare trials. A significant increase in registered COS studies on Core Outcome Measures
22 in Effectiveness Trials (COMET) website reflected the increasing awareness of the
23 unwarranted variation in outcome collection and reporting [10]. However, it is worthy to note
24 that the purpose of a standardized outcome set, or COS is not to create new outcomes, but to
25 select those outcomes which matter the most to the various stakeholders such as clinicians,
26 researchers, policy makers and patients.
27
28
29
30
31
32
33
34
35
36

37
38 In China, there is increasing emphasis on the development of TCM for chronic disease
39 care and prevention, with an increased usage of TCM related interventions on chronic
40 diseases, particularly in heart disease, stroke, cancer and diabetes [11]. This is reflected by
41 the uniqueness of TCM in its ability to treat patients by altering their “inner environment” or
42 simply, to regulate as a whole in the form of improving the patient’s physical function, self-
43 adaptive ability and immune function, which is beneficial for chronic diseases management
44 and prevention. With more research on TCM being carried out in China, guidance to improve
45 the value of trials and provide strong evidence to evaluate the true effectiveness of TCM
46 treatments is urgently required.
47
48
49
50
51
52

53
54 At present, there are two related COSs for HF recorded in the COMET database. The
55 Heart Failure Association of the European Society of Cardiology (HFA-ESC) developed a
56 consensus for HF endpoints in clinical trials published in 2013, with a 1 year follow up on the
57 defined outcomes across different regions between May 2011 and April 2013, reflecting on
58
59
60

1
2
3 the higher rate for all-cause mortality in acute HF than CHF across the 1 year span [12-13].
4
5 Another was the 17-item standardized set of outcome measurement for HF established by
6
7 The International Consortium for Health Outcomes Measurement (ICHOM) on March 2020,
8
9 which selectively addressed functional, psychosocial, burden of care, and survival outcome
10
11 domains [14]. Though the stakeholders involved in the COS development for HF represented
12
13 an international perspective and included patient-reported outcomes, the standardized
14
15 outcome set in both COSs may be biased toward Western patient populations, lacking
16
17 engagement in the Chinese patient population and Chinese healthcare professionals, and does
18
19 not involve any outcomes related to TCM syndromes or its characteristics. Therefore, it is
20
21 important to develop a COS that specifically address the need of CHF studies using TCM
22
23 treatment, which can represent all stakeholders for this specific intervention. The COS will
24
25 include outcomes with TCM characteristics and achieve consensus in Chinese research or
26
27 clinical experts and its patient population.

27 **Objective**

28
29 Currently, there is no study on COS development for CHF in TCM related clinical studies.
30
31 The objective of this study is to develop a COS-TCM for CHF (COS-TCM-CHF) and this
32
33 study protocol is written with reference to the Core Outcome Set-STAndards for Reporting
34
35 (COS-STAR) [15], the Core Outcome Set-STAndards for Development (COS-STAD) [16]
36
37 and the Core Outcome Set-STAndardised Protocol Items (COS-STAP) statement [17].
38

39 **Scope**

40
41 The health condition for this study is on CHF. CHF patients aged 18 and above will be
42
43 included. This COS will cover all TCM related interventions, including herbal medicine
44
45 decoction, Chinese patent medicine, extracts of herbal medicine, intravenous Chinese
46
47 medicine, acupuncture, cupping, Tuina, moxibustion and other rehabilitation therapy of
48
49 TCM. The COS-TCM-CHF will be implemented in all future studies that examine outcomes
50
51 of TCM related interventions for CHF.
52

53 **Registration**

54
55 This COS study has been registered on the COMET website (study 1486, available at
56
57 <http://www.comet-initiative.org/Studies/Details/1486>)
58
59
60

METHODS AND ANALYSIS

Steering committee membership

The steering committee will include 10 members, who are experts from different research fields. They include 3 TCM and 3 Western medicine clinical experts in the field of cardiology, 2 methodologists, 1 journal editor, 1 COS developer and 1 patient representative with CHF. The steering committee will review this protocol and provide guidance at each stage of the study process, as well as resolving any disagreements during the process. The committee will also attend and facilitate the consensus meeting as well as to engage COS uptake in the post development stage. All members of the steering committee membership will be co-authors of the COS-TCM-CHF.

Working group

The working group will be made up of 15 members, including TCM and Western medicine clinicians, methodologists, as well as professors and postgraduates from Chinese Clinical Trials COS Research Centre (ChiCOS), Tianjin University of TCM (TJUTCM), China. The role of the working group will include organising regular meetings, facilitating communication and hold discussion meetings to seek advice from the Steering committee if there are any differences to be resolved.

Stakeholders involvement

We will invite 7 groups of stakeholders to participate in the development of COS-TCM-CHF, which include healthcare professionals, patients or their representatives, COS developers, COS users (clinical trialists, systematic reviewers and clinical guideline developers), methodologists, policy makers and journal editors. The recruitment of stakeholders is as follows:

1. Western medicine and TCM healthcare professionals specialising in cardiology, with at least 5 years of clinical experience and academic qualifications of postgraduate and above. They will be selected from the China Association of Chinese Medicine (CACM) and Chinese Society of Cardiology (CSC).

2. Patients diagnosed with CHF possessing a moderate level of literacy and communication from inpatient wards and outpatient clinics of 4 TJUTCM affiliated hospitals.
3. COS developers, especially with relevant TCM experience via searching published or ongoing COS studies registered on COMET website.
4. Methodologists, COS users and journal editors will be invited by sampling with the help of the Chinese Cochrane Centre and TJUTCM Evidence-Based Medicine (EBM) Research Centre.
5. Policy makers in public health decision will be selected by CACM.

Patient and public involvement

Patients or their representatives will be involved in the semi-structured interviews, two rounds of Delphi survey and the final consensus meeting. We will recruit patients or their representatives with adequate communication skills. Addressing outcomes that are important to patients is crucial for COS-TCM-CHF development, hence patients' experiences in the management of CHF will contribute to a large extent in the development process.

Design

The study design for COS-TCM-CHF has been informed by COMET Initiative Handbook, with reference to the guidelines from COS-STAD recommendations and COS-STAP, which will be conducted in five stages (Fig.1):

1. Identifying potential outcomes and constructing an outcome pool. (Stage 1)
2. Merging outcomes and grouping under outcome domains (Stage 2)
3. Generating a preliminary list of outcomes. (Stage 3)
4. Conducting a 2-round Delphi survey to select candidate items for consensus meeting. (Stage 4)
5. Hold a consensus meeting to determine the final COS-TCM-CHF. (Stage 5)

Stage 1 Identifying potential outcomes and constructing an outcome pool

The purpose of COS development is not to create new outcomes, but to identify the most important outcomes to healthcare professionals, researchers, patients and public health decision makers in a specific healthcare field or disease, through a consensus process. We

will identify potential outcomes by constructing an outcome pool for COS-TCM-CHF development through the four steps:

1. Conducting systematic review to collect currently reported outcomes from published literature in TCM related clinical studies for CHF.
2. Identifying potential outcomes reported in international and Chinese clinical trial registry databases.
3. Patients' semi-structured interviews to collect outcomes which matter most to the patients or their representatives.
4. Clinicians' questionnaire survey to collect outcomes which are of interest to the healthcare professionals

Step 1: Systematic review of published literature

Search Strategy

We will conduct a comprehensive search strategy from 9 English and Chinese databases. 4 English databases include PubMed, the Cochrane Library, Embase and Web of Science and 5 Chinese databases include China National Knowledge Infrastructure (CNKI), WanFang Database (WanFang), SinoMed, Chinese Scientific Journal Database (VIP) and TCM Clinical Evidence Database System (EVDS-TCM). Randomized clinical trials (RCTs) of CHF with TCM related interventions published in from 2015 to 2020 will be included. The search strategy for English database is shown in Supplementary file 1.

Eligibility criteria

The inclusion and exclusion criteria for the systematic review of published literature is shown in Table 1.

Table 1 Inclusion and Exclusion criteria of the systematic review for published literature

	Inclusion criteria	Exclusion criteria
Types of literature	Randomized controlled trials	Unable to retrieve full texts

Participant	Patients diagnosed with CHF*, above 18 years of age	Patients with other comorbidities or in a more critical condition
Intervention	<ul style="list-style-type: none"> Intervention in treatment group: TCM related treatments which include oral or intravenous herbal medication, Chinese patent medicine, acupuncture, Tuina and acupoint application. Intervention in control group: No limitation 	None
Outcomes	No restriction	No reported outcomes
Language	Chinese and English	Published in Chinese non-core journals

*According to "Guidelines for the diagnosis and treatment of Heart failure in China (2018)" or "American College of Cardiology/American Heart Association (ACC/AHA) guidelines (2016)"

Literature screening and data extraction

Two reviewers will independently screen the literature, extract data and cross-check them according to the inclusion and exclusion criteria. For the missing information of some studies, we will try our best to contact the relevant authors to provide them. If not possible, the study will be excluded. Any disagreements will be resolved through discussion after a thorough reading of the paper or by consulting with the third researcher. An extraction table will be designed by the working group to collect relevant information on the study design, setting, demographics of participants, types of intervention and outcomes. Data extracted on the outcomes reported will include the name, definition, measurement timepoints and measurement instruments or methods. Four principles of data extraction are as follows:

1. Data extracted will be performed by two reviewers which will then be compared and cross-checked. Any disagreements will be resolved by a senior researcher.
2. Outcomes extracted will be reported verbatim to ensure authenticity and traceability from the original data.

3. The free-text field is placed in the extraction table to record special circumstances at any time.

4. Any alteration of the data extracted during the process will be recorded.

Furthermore, we will assess the reporting quality of outcomes reported in the included studies. The method of this assessment is shown in Table 2 with reference to other COS studies [18-20].

Table 2 Seven items assessment of the reporting quality of outcome measures

No.	Criterion	Yes	No
1	Whether the outcome was clearly stated as primary or secondary outcome.	1 point	0 point
2	Whether the outcome was defined or not. Outcomes were considered defined if text of their meaning or a citation was provided.	1 point	0 point
3	It was clearly described how the outcomes are measured or the outcome measurement (indicators and/or tools used, if relevant).	1 point	0 point
4	It was clearly described by whom the outcomes are measured.	1 point	0 point
5	It was clearly described the time points and time period at or during which outcome was measured.	1 point	0 point
6	Are methods used to enhance the quality of outcome measurement (for example, repeated measurement, training) if appropriate?	1 point	0 point
7	The reporting of outcomes was consistent throughout the article. There is no unambiguous reporting that makes it confusing for the reader to assess what has been done.	1 point	0 point

Step 2: International and Chinese clinical trial registry databases

We will search Chinese Clinical Trial Registry (ChiCTR) and Clinical trials.gov registry using the key word “heart failure” from inception to 2020. The protocols registered of CHF RCTs with TCM interventions will be included with reference to the same inclusion and exclusion criteria listed in Table 1. For literature screening and data extraction of clinical trial registration protocols, similar technique will be applied as per the above-mentioned systematic review of published literature. Subsequently, data extracted will be analysed and

1
2
3 outcomes will be aggregated with the list of potential outcomes derived from systematic
4 review of published literature, patients' semi-structured interviews and clinicians'
5 questionnaire surveys (as described in Method 3 and 4 later). Additionally, the reporting
6 quality of outcome measures from registered clinical studies will also be assessed using the
7 quality assessment score in Table 2.
8
9
10
11

12 13 **Step 3: Patients' semi-structured interview**

14 15 16 *Participant selection and recruitment*

17
18 Patients ≥ 18 years of age, diagnosed with CHF (according to the clinical guidelines for the
19 diagnosis and treatment of chronic heart failure in China or "American College of
20 Cardiology/American Heart Association (ACC/AHA) guidelines 2016") previously or
21 currently under TCM treatment as well as their family members or caregivers will be invited
22 to participate in the semi-structured interview. Potential participants will be approached at the
23 cardiology department of inpatient wards and outpatient clinics in Grade 3A TJUTCM
24 affiliated First Hospital and TJUTCM affiliated Second Hospital, Grade 2A TJUTCM
25 affiliated Fourth Hospital, as well as TJUTCM affiliated BaoKang Community Hospital.
26 Patients or their representatives should possess a moderate level of literacy and
27 communication skills to ensure effective communication. Patients who are cognitively
28 impaired or have serious comorbidities will be excluded from the study. Informed consent is
29 necessary to recruit participants into this study. All potential participants will be informed by
30 a member of the research team, that they are under no obligation to take part and are free to
31 withdraw from the study at any time without their medical care or legal rights being affected.
32 In the event whereby the recruited patients have a language or communication barrier, they
33 will be represented by their caregivers.
34
35
36
37
38
39
40
41
42
43
44
45
46

47 48 *Sampling size*

49
50 Patients' perspective is important and essential throughout the development process.
51 Sampling for qualitative interviews should aim for a diversity of participants [21]. We will
52 consider the gender, age, CHF classification and treatment history of the potential
53 participants. As there is no guideline or consensus on the sample size of this qualitative
54 research, and with past experience of semi-structured interviews done in COS studies [22,23],
55 we aim to recruit a sample size of 50 patients.
56
57
58
59
60

Data collection

The semi-structured interview will be conducted by qualified and trained investigator to explain the study to the participants. Study information sheets will be given to participants and informed consent will be collected before interviews are commenced. A questionnaire in Chinese language will be designed in advance for this semi-structured interview. A medical history and additional socioeconomic and demographic information on all participants will be collected. The investigator will ask the participants what outcomes are of importance to them in a face-to-face interview. In the event where a participant is not able to answer, the trained investigator will provide the list of outcomes collected from the systematic review of published literature and registered studies as a guide to inform participants on outcomes. In addition, an open-ended question will be asked to allow participants provide any other outcome which they consider important. The interviewer will then populate the questionnaire with the participant's answer. All interviews will be audio-recorded to aid detailed data analysis.

As the educational level of participants may vary, the questionnaires will be written using plain English or spoken Chinese for ease of understanding. The working group will carry out pilot-testing to establish if the questionnaire is user friendly. Where possible, professional jargon will be changed into plain English or spoken Chinese to ease comprehension for participants. The outline of the semi-structured interview is as listed below:

1. "What kind of result from the CHF treatment do you think is the most important to you?"
2. "What is the change in your CHF management, symptoms or daily lifestyle do you consider to be the most important in helping you to determine the effectiveness of the treatment?"
3. "Which aspect of CHF treatment is of most concern to you or which aspects do you hope to get better improvement?"
4. "Are there any changes after the treatment of CHF? If yes, what changes have made you feel better or even worse than before?"

Step 4: Clinicians' questionnaire survey

Participant selection and recruitment

1
2
3 Healthcare professionals, including TCM and western practitioners specialising in cardiology
4 with ≥ 5 years of clinical experience and a master's degree or above will be invited to
5 participate in the questionnaire surveys. Potential candidates will be approached at hospital
6 wards and outpatient clinics of TJUTCM affiliated First Hospital, TJUTCM affiliated Second
7 Hospital, TJUTCM affiliated Fourth Hospital and TJUTCM affiliated BaoKang Community
8 Hospital. Participation will be on a voluntary basis and informed consent is required if they
9 agreed to participate in the survey.
10
11
12
13
14
15

16 ***Sampling size***

17
18
19 Though the outcomes collected will be more comprehensive if the sample size is larger, we
20 considered the feasibility and representativeness of the surveys. Generally, sampling in
21 qualitative studies is purposive, therefore the clinicians who will participate should range
22 from medical officers to senior experts in the field of cardiology. There is currently no
23 guideline for the sampling size for qualitative studies, hence based on our past experience and
24 previous COS studies, we will recruit a sample size of 80 participants. In the event when less
25 than 80 surveys are completed, there will be a further recruitment of clinicians from national
26 cardiology academic conferences until the sample size is reached.
27
28
29
30
31
32
33

34 **Data collection**

35
36
37 A predesigned questionnaire in paper form will be distributed to the healthcare professionals
38 or clinicians. Demographics information, educational and academic status of the clinicians
39 will be collected upon agreement to complete the questionnaire survey. Questionnaires are
40 being designed in an open-ended format and clinicians will have the freedom to fill in
41 outcomes which are of importance to them. There will be a limit to a maximum of 5
42 outcomes listed in order to achieve the selection of outcomes which are of high importance to
43 the clinicians. The list of outcomes collected from the questionnaires will be analysed by the
44 working group.
45
46
47
48
49
50
51

52 **Data analysis**

53
54
55 Data analysis will be performed after collecting data from the 4 different methods. Outcomes
56 collected from literature or clinical registry databases as well as qualitative research (patients'
57 semi-structured interviews and clinicians' questionnaire surveys) will be imported into an
58
59
60

1
2
3 Excel table. These outcomes collected will form the outcome pool. The outcomes will be
4 labelled with numbers corresponding to the original studies or qualitative surveys for easy
5 reference and traceability. Upon completion of outcome labelling, the outcomes will then be
6 cross-checked and standardized. The methods of standardizing outcomes are as follows:
7
8
9

- 10
11 1. The outcomes are sorted according to their similarities.
- 12
13 2. Extracted verbatim of the outcomes will be standardized according to their original
14 description or definition, in order to address problems such as abbreviations, nicknames and
15 composite outcomes. The composite outcome will be separated into individual outcomes.
16
17 3. Duplicates will be removed from the outcome pool. Similar and overlapping outcomes will
18 be merged into their standardized terminologies.
19
20 4. Two researchers of the working group will record the corresponding number assigned to
21 the outcomes in the list as well as record the frequency of each outcome.
22
23
24
25
26
27

28 Finally, an outcome pool is constructed after the outcomes are standardized. The steering
29 committee will be consulted if there were any discrepancies in the process of outcome
30 standardization. And if there is no consensus reached on an outcome, the outcome will be
31 excluded.
32
33
34
35

36 **Stage 2 Merging outcomes and grouping under outcome domains**

37
38 After an outcome pool is constructed, outcomes will be merged and grouped under their
39 respective outcome domains recommended in previous COS studies [24]. Since COS-CHF-
40 TCM focuses on developing a set of outcomes to be implemented in TCM related studies, the
41 outcome classification with TCM characteristics will be added such as TCM syndrome
42 scoring scale. The process will be carried out by two researchers independently. After which
43 the classification of outcomes will be cross-checked. Any discrepancies will be resolved by a
44 third researcher from the steering committee.
45
46
47
48
49
50

51 **Stage 3 Generating a preliminary list of outcomes**

52
53 The outcome pool can be used as a preliminary list of outcomes in the questionnaire of the
54 Delphi process. However, this list of outcomes can be a long list. If the list of outcomes from
55 the outcome pool is directly taken as the preliminary list of outcomes, it may result in a low
56 response during Delphi survey. Based on previous experience in developing a COS,
57
58
59
60

1
2
3 participants involved in the Delphi survey were less willing to respond when there was a
4 large number of outcomes in the preliminary list, for instance needing more than 10 minutes
5 to complete the questionnaire. Furthermore, the scores of outcomes are likely to be too
6 concentrated, making it difficult to reach a consensus on the ranking of importance. As a
7 result, multiple rounds of Delphi survey will be required which lead to additional time and
8 resource wastage.
9

10
11 Therefore, it is important to shorten the list of outcome pool to establish a preliminary list of
12 outcomes, which of a suitable length to be used in the Delphi survey later (Stage 4). The
13 criteria for retaining or dropping the outcomes are as follows:
14

- 15 1. If the number of outcomes collected in the outcome pool is less than or equal to 100, all
16 outcomes will be retained in the preliminary list.
- 17 2. If the number of outcomes collected in the outcome pool is more than 100, the working
18 group will conduct an internal vote to drop the items in the outcome pool under the guidance
19 of the steering committee. If 90% of the members in the working group think that an item is
20 unnecessary to enter the preliminary list, the item will be removed. The remaining items will
21 then be included to form the preliminary list of outcomes.
22
23
24
25
26
27
28
29
30
31
32

33 **Stage 4 2-round Delphi survey**

34 *Software*

35
36 The 2-round electronic Delphi survey will be conducted using a Delphi software developed
37 by ChiCOS, similar to the DelphiManager software implemented by COMET working group
38 for COS research. The Delphi software is programmed using Chinese language to cater to the
39 stakeholder groups in China. According to the preliminary list of outcomes, it can
40 automatically generate questionnaire for the Delphi survey and to display results of outcome
41 scoring from the participants and comparison over different stakeholder after each round of
42 survey is completed. The Delphi software is also equipped with a database containing the
43 information of pre-existing Delphi participants or experts shared by ChiCOS working group.
44
45
46
47
48
49
50
51

52 *Selection of Delphi participants and sampling size*

53
54 Seven stakeholder groups will be invited to participate in the Delphi survey, which include
55 clinicians, CHF patients or their representatives, experienced COS developers,
56 methodologists, potential COS users (clinical trialists, systematic reviewers, clinical guideline
57
58
59
60

1
2
3 developers, etc.), policy makers and journal editors. The 3 key stakeholder groups as
4 mentioned in COS-STAD, namely the clinicians, patients or their representatives and COS
5 users are essential in COS development. Hence, we will invite at least 40 participants for
6 each of the 3 key stakeholder groups. For the group of clinicians, a 1:1 ratio will be fixed for
7 Western medicine doctors and TCM doctors. At least 15 participants will be invited for each
8 of the remaining stakeholder groups. We plan to invite approximately 210 participants for the
9 Delphi survey. It is beneficial for more participants to represent each stakeholder group in
10 order to convince future patients or other stakeholders of its value. Hence, there is no need to
11 specify an upper limit for the number of participants. The selection criteria for participants
12 from the different stakeholders was previously stated in the “Stakeholders involvement”
13 section. Relevant information of the selected participants (excluding patients) will be
14 recorded in the Delphi experts’ database system on ChiCOS website. It is noteworthy to
15 identify the pre-existing Delphi participants name list available on Delphi database system on
16 ChiCOS website shared by members of ChiCOS working group as well as other COS
17 developers. This set of name list can be used to supplement the Delphi participants for this
18 study.
19
20
21
22
23
24
25
26
27
28
29
30

31 *Delphi scoring*

32
33
34 The Delphi process will require each participant to consider the importance of each outcome
35 from the four aspects, namely importance on clinical value, recognizability of outcomes in
36 related studies, able to reflect the advantages of TCM effectiveness, as well as being
37 consistent and measurable. Participants will be asked to score each of the outcome items in
38 the preliminary checklist using a scoring scale of 1 to 9, with 1 to 3 is labelled as ‘not
39 important’, 4 to 6 labelled as ‘important but not critical’ and 7 to 9 labelled as ‘critical’ [25].
40 Participants will have an option of ‘unsure’ if they are unable to assess the importance of the
41 outcome items.
42
43
44
45
46
47
48

49 **Delphi round 1**

50
51 The preliminary list of outcomes generated in Stage 3 will be used in the first round of Delphi
52 survey. For the questionnaire of Delphi round 1, a brief summary of the COS study will be
53 presented to the participants. Participants will need to select which stakeholder group they
54 belong to and be asked to score all the outcome items. At the end of the questionnaire, there
55 is an additional open question, “What other outcomes do you think are important but not
56 included in this questionnaire?”, to allow participants to add new outcomes. Besides,
57
58
59
60

1
2
3 participants will have the option to provide their suggestion in a free-text field at the end of
4 each item. Upon agreeing to participate in the Delphi survey, participants are required to
5 score all outcome items. If the list of questions in the survey is not completed, there will be a
6 reminder to avoid any missing data. Participants will not be able to submit any incomplete
7 questionnaire so as to ensure the integrity of the survey. In order to ensure the
8 comprehensibility of the questionnaire, we will invite a language expert to assist in revising
9 the outcome terminology into plain language. The questionnaire will be pilot-tested on a
10 small group of participants before disseminating to all participants.

11
12 Participants (excluding patients) will be sent a personalised email outlining the study along
13 with a link to the online questionnaire of Delphi round 1. And they will be asked to complete
14 the survey within 3 weeks. A reminder email will be sent out at the end of week 2 to prompt
15 completion of the survey. An inspection to assess the number of participants will be done
16 near the end of week 2 by the working group. If the response rate of the Delphi survey
17 (number of respondents / number of invited participants) is lower than 70%, the survey will
18 be extended for 2 more weeks and a reminder email will be sent to the respective participants
19 who did not respond. For the stakeholder group of patients or their representatives, the survey
20 will be conducted face-to-face in inpatient wards or outpatient clinics by a trained
21 investigator to complete the paper questionnaire. Both the online and paper questionnaires are
22 of the same version. All participants are asked to score each item according to their
23 importance. After completing the rating score, they will have the opportunity to add any other
24 item which is not in the list but important to them.

25
26 The working group will collect all completed questionnaires and calculate the overall
27 participant response rate for Delphi round 1. For each outcome item, the average score, the
28 score distribution across different stakeholder groups as well as the number of participants
29 from different stakeholders who have scored it will be summarized. If $\geq 70\%$ of the
30 participants in any stakeholder group considered the item to be “important” or “critical” (ie.
31 score of 4-9 points), the item will be included in the next round of Delphi. At the same time,
32 the working group will inspect and determine whether the newly added items by the
33 participants are duplicates in the preliminary list and only new and unique outcome will be
34 retained to be included in the next round for scoring. Duplicates or overlapping outcomes will
35 be removed and not enter the next round.

36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 **Delphi round 2** 60

1
2
3 Participants who completed the first round will be invited to participate in Delphi round 2.
4 Response rate, the distribution of scores and participants' own score for each outcome are
5 being presented to all participants. After considering the feedback from the first round,
6 participants will be asked to re-score the retained outcomes which have met the requirement
7 to enter the second round and score the newly added outcome items from the first round. If
8 the scores between the two rounds change drastically, for example a participant considered an
9 item in round 1 as "not important" (1-3points) and rescores the item as "critical" (7-9 points)
10 in round 2, he or she will need to provide the reason for the change in scores in the free-text
11 field. Participants are also able to provide any suggestions for each item in the survey.
12
13
14
15
16
17
18

19 Delphi round 2 survey will also be sent out electronically to all participants (excluding
20 patients or their representatives) by the Delphi software developed by ChiCOS. The survey
21 will be printed into hard copy similar to Delphi round 1 for patients to complete in the second
22 round. The survey should be completed within 3 weeks and a reminder email will be sent to
23 prompt completion of the survey at the end of week 2. If the response rate is lower than 70%,
24 the survey will be extended for 1 more week and a reminder email will be sent to the
25 respective participants who did not respond.
26
27
28
29
30
31

32 At the end of Delphi round 2, the participants' response rate, the average score as well as the
33 score distribution for each outcome item are calculated. Participants' score changes between
34 round 1 and 2 will be examined and verified, as well as summarizing the reasons for the
35 change in scores. Together with the reasons, the average score for each outcome in round 2 is
36 compared with that in round 1, so that we can assess attrition bias. There will not be any
37 source for missing data as we have made it compulsory for participants to complete all the
38 questions in the Delphi survey before submission.
39
40
41
42
43
44

45 **Stage 5 Consensus meeting**

46
47 The final phase of the developing COS-TCM-CHF is to hold a face-to-face consensus
48 meeting after the Delphi process. The consensus meeting will be a one day event and 35
49 participants will be invited to confirm the final outcomes for COS-TCM-CHF. The consensus
50 meeting will be held in Tianjin, China for the convenience of most participants. In the event
51 where there are other major events such as the resurgence of Coronavirus outbreak, the
52 meeting will be changed to online video conference.
53
54
55
56
57

58 **Recruitment**

We will invite participants from the different stakeholder groups who have completed the two rounds of Delphi survey to join the consensus meeting. Experts of the steering committee and members of the working group will also attend the meeting. We will draw lots to select representatives of the participants from each stakeholder group, including patient participants. If a representative from a stakeholder group is not available to attend the meeting, he or she will be replaced by another participant from the same stakeholder group.

Consensus definition

Consensus criteria will be specified a priori. The definition of the consensus is shown in Table 3, which was made according to the consensus previously used by other COSs developed and COMET recommendations [9,21,26]. Outcomes are classified into 3 categories: ‘consensus in’, ‘consensus out’ and ‘no consensus’.

Table 3 Consensus definition		
Consensus classification	Description	Definition
Consensus in	Consensus that outcome should be included in COS	>70% of participants scoring 7-9 and <15% of participants scoring 1-3
Consensus out	Consensus that outcome should not be included in the COS	>70% of participants scoring 1-3 and <15% of participants scoring 7-9
No consensus	Uncertainty about importance of the outcome	Anything else

Consensus process and final decisions

After a short review of the COS-TCM-CHF study, the scoring results of Delphi round 2 will be shown to all participants in the meeting. According to the consensus definition, outcomes of “consensus in” will be prioritised to be included in the final COS and outcomes of “consensus out” will be excluded. The participants will vote anonymously for the outcomes rated as “no consensus”. After the voting, results will be calculated and outcomes achieving a consensus will enter the final COS-TCM-CHF. In the process, all participants have the opportunity to discuss any outcome. If there are any disputes, it will be settled by the Steering committee through the nominal group technique (NGT) [27]. The final COS-TCM-CHF will be developed which will include 4-10 core outcomes according to the COMET

1
2
3 recommendations [21].
4
5

6 **Fig. 1** Flow chart of the study design for COS-TCM-CHF
7

8 ***List of abbreviations***
9

10
11 heart failure (HF), chronic heart failure (CHF), core outcome set (COS), traditional Chinese
12 medicine (TCM), Core outcome set on Traditional Chinese medicine (COS-TCM), Core
13 outcome set on Traditional Chinese medicine for chronic heart failure (COS-TCM-CHF),
14 Heart Failure Association of the European Society of Cardiology (HFA-ESC), The
15 International Consortium for Health Outcomes Measurement (ICHOM), Core Outcome
16 Measures in Effectiveness Trials (COMET), Core outcome set-STANDARDISED Protocol (COS-
17 STAP), reporting guidelines for studies developing COS protocol (COS-STAR), Chinese
18 Clinical Trials COS Research Centre (ChiCOS), Tianjin University of TCM (TJUTCM),
19 Core outcome set-STANDARDS for Development (COS-STAD), randomized clinical trials
20 (RCTs)
21
22
23
24
25
26
27
28
29

30 ***Ethics and dissemination***
31

32 The study has obtained ethical approval through the Ethics Committee of the Evidence-based
33 Medicine Centre, Tianjin University of Traditional Chinese Medicine, Ref:
34 TJUTCMEC201200002. Informed consent will be obtained from all participants who
35 participate in the semi-structured interviews, questionnaire survey and two rounds of the Delphi
36 survey. The study is registered with the COMET Initiative
37 (<http://www.cometinitiative.org/Studies/Details/1486>).
38
39
40
41
42
43

44 When the development of the COS is completed, it will be reported based on the items of the
45 Core Outcome Set-STANDARDS for Reporting (COS-STAR). The findings will be submitted for
46 publication in peer-reviewed and open access journals and will be presented at national and
47 international conferences on CHF. In addition, the results will be disseminated on the website
48 of Chinese clinical trials of COS ([www. Chicos.org.cn](http://www.Chicos.org.cn)). In addition, with the help of ChiCOS
49 and the China association of Chinese medicine, we hope to promote awareness of the COS
50 results and we intend to send the publication of the COS to all participants via emails or express
51 delivery to improve COS-TCM implementation.
52
53
54
55
56
57

58 ***Author affiliations***
59
60

1
2
3 1 Evidence-based Medicine Centre, Chinese Medicine Institute, Tianjin University of
4 Traditional Chinese Medicine, Tianjin, China
5
6

7
8 2 Chinese Clinical Trials Core Outcome Set Research Centre, Tianjin, China
9

10 *Authors' contributions*

11
12
13 MZ and HZC wrote the paper and conceived the project. MZ and HZC contributed equally to
14 the manuscript. HZC contributed to the English translation of this protocol. MZ and JZ are the
15 principal investigators of the study, and MZ obtained the support of the National Natural
16 Science Foundation of China. HZC, BN and KL are responsible for conducting the systematic
17 review. WZ and BZ provide supervision for the project. All authors edited and critically revised
18 the study protocol. All authors have read, contributed to and approved the manuscript.
19
20
21
22
23

24 *Funding*

25
26
27 This work was supported by the National Natural Science Foundation of China
28 (No.81473544).
29

30 *Competing interests*

31
32 All authors declare that they have no competing interests.
33
34

35 *Patient and public involvement*

36
37 Patients and/or the public were involved in the design, or conduct, or reporting, or
38 dissemination plans of this research. Refer to the Methods section for further details.
39
40

41 *Patient consent for publication*

42
43 Not required
44

45 *Provenance and peer review*

46
47 Not commissioned; externally peer reviewed.
48
49

50 *Open access*

51
52 This is an open access article distributed in accordance with the Creative Commons
53 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,
54 remix, adapt, build upon this work non-commercially, and license their derivative works on
55 different terms, provided the original work is properly cited, appropriate credit is given, any
56 changes made indicated, and the use is non-commercial. See:
57
58
59
60

1
2
3 <http://creativecommons.org/licenses/by-nc/4.0/>.

4
5
6 **ORCID iDs**

7
8 Mingyan Zhang <https://orcid.org/0000-0002-4413-7784>

9
10 Hui Zi Chua <https://orcid.org/0000-0003-3927-9179>

11
12 Bohan Niu <https://orcid.org/0000-0002-3092-9879>

13
14 Kai Li <https://orcid.org/0000-0003-2724-338X>

15
16 Wenke Zheng <https://orcid.org/0000-0001-7963-5946>

17
18 Junhua Zhang <https://orcid.org/0000-0003-4043-1967>

19
20
21
22 ***Consent for publication***

23
24 Not applicable

25
26
27 ***Availability of data and materials***

28
29 Not applicable

30
31
32 **References:**

- 33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016;18(8):891-975. doi:10.1002/ejhf.592
 2. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation*. 2020;141(9):e139-e596. doi:10.1161/CIR.0000000000000757
 3. R. Ariely et al. Heart Failure in China: A review of literature. *Drugs* 2013, 73(7):689-701.
 4. Jun Huang. Epidemiology characteristics and preventive strategies of heart failure in China. *Chinese Journal of Heart and Rhythm Electronics* 2015,3(2):2-3.
 5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013
 6. Q Jia, L Wang, X Zhang et al. Prevention and treatment of chronic heart failure through traditional Chinese medicine: Role of the gut microbiota. *Pharmacological Research*. *Pharmacological Research* 151 (2020) 104552.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
7. Wang Y, Wang Q, Li C, et al. A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure. *Curr Pharm Des.* 2017;23(34):5115-5124.
 8. Zhang L, Zhang J, Chen J, et al. Clinical Research of Traditional Chinese Medicine Needs to Develop Its Own System of Core Outcome Sets [J]. *Evidence-Based Complementary and Alternat Med*, 2013; 2013:202703.
 9. Williamson, P.R., Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider[J]. *Trials*, 2012. 13: p.132.
 10. Elizabeth Gargon, Sarah L. Gorst, Paula R. Williamson. Choosing important health outcomes for comparative effectiveness research: 5th annual update to a systematic review of core outcome sets for research[J]. *PLoS ONE* 14(12): e0225980.
 11. Fan X, Meng F, Wang D et al. Perceptions of traditional Chinese medicine for chronic disease care and prevention: a cross-sectional study of Chinese hospital-based health care professionals. *BMC Complement Altern Med.* 2018 Jul 6;18(1):209.
 12. Zannad F, Garcia AA, Anker SD et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail.* 2013 Oct;15(10):1082-94.
 13. Crespo-Leiro MG, Anker SD, Maggioni AP et al. Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail.* 2016 Jun;18(6):613-25. doi: 10.1002/ejhf.566. Erratum in: *Eur J Heart Fail.* 2017 Mar;19(3):438.
 14. Burns DJP, Arora J, Okunade O et al. International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients. *JACC Heart Fail.* 2020 Mar;8(3):212-222.
 15. Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, et al. (2016) Core Outcome Set–STAndards for Reporting: The COS-STAR Statement. *PLoS Med* 13(10): e1002148.
 16. Kirkham JJ, Davis K, Altman DG, et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations[J]. *PLoS Med*, 2017. 14(11): p. e1002447.
 17. Kirkham, J.J., Gorst, S., Altman, D.G. *et al.* Core Outcome Set-STANDARDISED Protocol Items: the COS-STAP Statement. *Trials* 20, 116 (2019).
 18. Harman NL, Bruce IA, Callery P, et al. MOMENT--Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials.* 2013;14:70
 19. Alkhaffaf B, Blazeby JM, Williamson PR, et al. Reporting of outcomes in gastric cancer surgery trials: a systematic review. *BMJ Open* 2018;8:e21796.
 20. Heemskerk SCM, Rotteveel AH, Melenhorst J, Breukink SO, Kimman ML, Dirksen CD. Heterogeneous outcome reporting in adult slow-transit constipation studies: Systematic review towards a core outcome set. *J Gastroenterol Hepatol.* 2020;35(2):192–203.

- 1
- 2
- 3
- 4 21. Williamson, P.R., Altman, D.G., Bagley, H. *et al.* The COMET Handbook: version
- 5 1.0. *Trials* 18, 280 (2017).
- 6
- 7 22. Tugwell P, Boers M. OMERACT conference on outcome measures in rheumatoid
- 8 arthritis clinical trials: introduction. *J Rheumatol* 1993;20:528–30.
- 9
- 10 23. Qiu R, Zhong C, Han S, et al. Development of a core outcome set for myocardial
- 11 infarction in clinical trials of traditional Chinese medicine: a study protocol. *BMJ*
- 12 *Open*. 2019;9(12):e032256.
- 13
- 14 24. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy
- 15 has been developed for outcomes in medical research to help improve knowledge
- 16 discovery. *J Clin Epidemiol*. 2018 Apr;96:84-92.
- 17
- 18 25. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE
- 19 guidelines: 2. Framing the question and deciding on important outcomes. *J Clin*
- 20 *Epidemiol*. 2011;64(4):395–400.
- 21
- 22 26. de Blacam C, Baylis AL, Kirschner RE, Smith SM, Sell D, Sie KCY, Harris HE, Orr
- 23 DJA. Protocol for the development of a core outcome set for reporting outcomes of
- 24 management of velopharyngeal dysfunction. *BMJ Open*. 2020 Aug 13;10(8):e036824.
- 25 doi: 10.1136/bmjopen-2020-036824. PMID: 32792441; PMCID: PMC7430341.
- 26
- 27 27. Wiggins ST, Colby S, Moret L, McElrone M, Olfert MD, Riggsbee K, Opoku-
- 28 Acheampong A, Kidd T. A Modified Nominal Group Technique (mNGT) - Finding
- 29 Priorities in Research. *Am J Health Behav*. 2020 May 1;44(3):345-352. doi:
- 30 10.5993/AJHB.44.3.7. PMID: 32295682.
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60




Fig. 1 Flow chart of the study design for COS-TCM-CHF

Supplementary File 1

#1 "chronic"[All Fields] OR "chronical"[All Fields] OR "chronically"[All Fields] OR "chronicities"[All Fields] OR "chronicity"[All Fields] OR "chronicization"[All Fields] OR "chronics"[All Fields] AND "heart failure"[MeSH Terms] OR "heart failure"[Title/Abstract] OR "cardiac failure"[Title/Abstract] OR "myocardial failure"[Title/Abstract] OR "cardiomyopath*"[Title/Abstract] OR "cardio renal syndrome"[Title/Abstract] OR "dyspnea paroxysmal"[Title/Abstract] OR "edema cardiac"[Title/Abstract] OR "heart failure diastolic"[Title/Abstract] OR "heart failure systolic"[Title/Abstract] OR "heart decompensation"[Title/Abstract] OR "decompensation heart"[Title/Abstract] OR "heart failure right sided"[Title/Abstract] OR "heart failure right sided"[Title/Abstract] OR "right sided heart failure"[Title/Abstract] OR "right sided heart failure"[Title/Abstract] OR "congestive heart failure"[Title/Abstract] OR "heart failure congestive"[Title/Abstract] OR "heart failure left sided"[Title/Abstract] OR "heart failure left sided"[Title/Abstract] OR "left sided heart failure"[Title/Abstract] OR "left sided heart failure"[Title/Abstract]

#2 "medicine, chinese traditional"[MeSH Terms] OR "chinese medicine"[Title/Abstract] OR "traditional chinese medicine"[Title/Abstract] OR "herbal medicine"[Title/Abstract] OR "chinese traditional"[Title/Abstract] OR "chinese herbal"[Title/Abstract] OR "oriental traditional"[Title/Abstract] OR "herb"[Title/Abstract] OR "herbs"[Title/Abstract] OR "Herbal"[Title/Abstract] OR "herbals"[Title/Abstract] OR "TCM"[Title/Abstract]

#3 "Acupuncture"[MeSH Terms] OR "acupuncture therapy"[MeSH Terms] OR "acupuncture treatment*"[Title/Abstract] OR "treatment acupuncture"[Title/Abstract] OR "therapy acupuncture"[Title/Abstract] OR "pharmacoacupuncture treatment"[Title/Abstract] OR (((((((("therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture therapy"[Title/Abstract]

#4 #2 OR #3 (((((((((((("medicine, chinese traditional"[MeSH Terms] OR "chinese medicine"[Title/Abstract]) OR "traditional chinese medicine"[Title/Abstract]) OR "herbal medicine"[Title/Abstract]) OR "chinese traditional"[Title/Abstract]) OR "chinese herbal"[Title/Abstract]) OR "oriental traditional"[Title/Abstract]) OR "herb"[Title/Abstract]) OR "herbs"[Title/Abstract]) OR "Herbal"[Title/Abstract]) OR "herbals"[Title/Abstract]) OR "TCM"[Title/Abstract]) OR (((((((("Acupuncture"[MeSH Terms] OR "acupuncture therapy"[MeSH Terms]) OR "acupuncture treatment*"[Title/Abstract]) OR "treatment acupuncture"[Title/Abstract]) OR "therapy acupuncture"[Title/Abstract]) OR "pharmacoacupuncture treatment"[Title/Abstract]) OR (((((((("therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture therapy"[Title/Abstract]) AND "randomized controlled trial"[Publication Type])

#5 #1 AND #4 (((((((((((((((((((((((("chronic"[All Fields] OR "chronical"[All Fields]) OR "chronically"[All Fields]) OR "chronicities"[All Fields]) OR "chronicity"[All Fields]) OR

1
2
3 "chronicization"[All Fields]) OR "chronics"[All Fields]) AND "heart failure"[MeSH Terms]
4 OR "heart failure"[Title/Abstract]) OR "cardiac failure"[Title/Abstract]) OR "myocardial
5 failure"[Title/Abstract]) OR "cardiomyopath*"[Title/Abstract]) OR "cardio renal
6 syndrome"[Title/Abstract]) OR "dyspnea paroxysmal"[Title/Abstract]) OR "edema
7 cardiac"[Title/Abstract]) OR "heart failure diastolic"[Title/Abstract]) OR "heart failure
8 systolic"[Title/Abstract]) OR "heart decompensation"[Title/Abstract]) OR "decompensation
9 heart"[Title/Abstract]) OR "heart failure right sided"[Title/Abstract]) OR "heart failure right
10 sided"[Title/Abstract]) OR "right sided heart failure"[Title/Abstract]) OR "right sided heart
11 failure"[Title/Abstract]) OR "congestive heart failure"[Title/Abstract]) OR "heart failure
12 congestive"[Title/Abstract]) OR "heart failure left sided"[Title/Abstract]) OR "heart failure
13 left sided"[Title/Abstract]) OR "left sided heart failure"[Title/Abstract]) OR "left sided heart
14 failure"[Title/Abstract]) AND (((((((("medicine, chinese traditional"[MeSH Terms] OR
15 "chinese medicine"[Title/Abstract]) OR "traditional chinese medicine"[Title/Abstract]) OR
16 "herbal medicine"[Title/Abstract]) OR "chinese traditional"[Title/Abstract]) OR "chinese
17 herbal"[Title/Abstract]) OR "oriental traditional"[Title/Abstract]) OR "herb"[Title/Abstract])
18 OR "herbs"[Title/Abstract]) OR "Herbal"[Title/Abstract]) OR "herbals"[Title/Abstract]) OR
19 "TCM"[Title/Abstract])) AND (((((((("medicine, chinese traditional"[MeSH Terms] OR
20 "chinese medicine"[Title/Abstract]) OR "traditional chinese medicine"[Title/Abstract]) OR
21 "herbal medicine"[Title/Abstract]) OR "chinese traditional"[Title/Abstract]) OR "chinese
22 herbal"[Title/Abstract]) OR "oriental traditional"[Title/Abstract]) OR "herb"[Title/Abstract])
23 OR "herbs"[Title/Abstract]) OR "Herbal"[Title/Abstract]) OR "herbals"[Title/Abstract]) OR
24 "TCM"[Title/Abstract]) OR (((((((("Acupuncture"[MeSH Terms] OR "acupuncture
25 therapy"[MeSH Terms]) OR "acupuncture treatment*"[Title/Abstract]) OR "treatment
26 acupuncture"[Title/Abstract]) OR "therapy acupuncture"[Title/Abstract]) OR
27 "pharmacoacupuncture treatment"[Title/Abstract]) OR (((((((("therapeutics"[MeSH Terms]
28 OR "therapeutics"[All Fields]) OR "treatments"[All Fields]) OR "Therapy"[MeSH
29 Subheading]) OR "Therapy"[All Fields]) OR "Treatment"[All Fields]) OR "treatment s"[All
30 Fields]) AND "Pharmacoacupuncture"[Title/Abstract])) OR "pharmacoacupuncture
31 therapy"[Title/Abstract]) AND "randomized controlled trial"[Publication Type]))
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60